deferiprone and Iron Overload studies

Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.

Iron Overload: An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)

Research Excerpts

Excerpt	Relevance	Reference
"This post hoc analysis of the phase 3b/4, randomized, open-label FIRST (Ferriprox in Patients with IRon Overload in Sickle Cell Disease Trial) study (NCT02041299) included patients 17 years and younger with SCD or other anemias receiving deferiprone or deferoxamine."	10.23	Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. ( Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Fradette, C; Hamdy, M; Inusa, B; Kanter, J; Kwiatkowski, JL; Lee, D; Temin, NT; Tricta, F; Veríssimo, MPA; Williams, S, 2024)
" The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited."	9.51	Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. ( Adly, AAM; Alshehri, A; Badr, M; Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Hamdy, M; Inusa, B; Kanter, J; Kilinc, Y; Kwiatkowski, JL; Lee, D; Tricta, F; Williams, S, 2022)
" Here, we used deferiprone (DFP) as an iron chelating agent in TI patients receiving intermittent blood transfusion who are asymptomatic for cardiovascular disease in order to evaluate the effectiveness in iron overload and reduce the possibility of cardiovascular complications."	9.15	Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. ( Akrawinthawong, K; Chaowalit, N; Chatuparisuth, T; Siritanaratkul, N, 2011)
"Oral deferiprone (L1) appears to be promising in the treatment of beta-thalassemia major (TM) patients."	9.12	Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. ( Capra, M; Cracolici, E; De Marchi, D; Lombardi, M; Maggio, A; Malizia, R; Midiri, M; Pepe, A; Positano, V; Prossomariti, L, 2006)
"Deferiprone is a safe and effective oral iron-chelating agent which can be used, under strict supervision, in transfusion-dependent iron overloaded children."	9.09	A trial of deferiprone in transfusion-dependent iron overloaded children. ( De Silva, DD; Fernandopulle, M; Fonseka, EA; Lucas, GN; Perera, BJ, 2000)
" Deferiprone is an oral iron chelator approved for use in the United States as a second line agent for the treatment of transfusional iron overload in patients with thalassemia."	8.95	Deferiprone for the treatment of transfusional iron overload in thalassemia. ( Belmont, A; Kwiatkowski, JL, 2017)
"To assess the effectiveness and safety of oral deferasirox in people with thalassaemia and iron overload."	8.95	Deferasirox for managing iron overload in people with thalassaemia. ( Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK, 2017)
"For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation."	8.83	Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. ( Neufeld, EJ, 2006)
"Iron mobilization from transferrin is one of the most important screening methods for the selection of chelators intended for clinical use in the treatment of iron overload in thalassemia and other conditions."	8.83	Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. ( Kontoghiorghes, GJ, 2006)
"Deferiprone (L1), and appropriate combinations with deferoxamine (DFO), can be used effectively for the treatment of thalassemia and other transfusional iron loading conditions."	8.83	Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. ( Kontoghiorghes, GJ, 2006)
" Iron removal in transfusional iron overload is achieved using chelation therapy with the chelating drugs deferoxamine (DF) and deferiprone (L1)."	8.80	Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). ( Hadjigavriel, M; Kolnagou, A; Kontoghiorghes, GJ; Pattichi, K, 2000)
"Iron-overload leads to gut dysbiosis/inflammation and disturbance of metabolites, and deferiprone alleviates those conditions more effectively in WT than in those that are thalassemic."	8.12	Deferiprone has less benefits on gut microbiota and metabolites in high iron-diet induced iron overload thalassemic mice than in iron overload wild-type mice: A preclinical study. ( Buddhasiri, S; Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kittichotirat, W; Kumfu, S; Nawara, W; Sarichai, P; Sriwichaiin, S; Thiennimitr, P; Thonusin, C, 2022)
" Children with thalassemia between 2 and 18 y of age with serum ferritin above 1500 ng/ml were started on oral deferiprone and deferasirox."	8.02	Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study. ( Delhikumar, CG; DivakarJose, RR; Ram Kumar, G, 2021)
"The present study failed to demonstrate that the use of deferiprone at >90 mg/kg/d was associated with increased risk of agranulocytosis or neutropenia, but did demonstrate more effective liver iron control in iron overload patients."	7.91	Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload. ( Binding, A; Kuo, KHM; Tomlinson, G; Ward, R, 2019)
"Data on the use of deferiprone in young children with iron overload are limited."	7.83	Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience. ( Chuansumrit, A; Kadegasem, P; Sasanakul, W; Sirachainan, N; Songdej, D; Wongwerawattanakoon, P, 2016)
"Use of the iron chelator deferiprone for treatment of iron overload in thalassemia patients is associated with concerns over agranulocytosis, which requires weekly absolute neutrophil counts (ANC)."	7.83	Deferiprone-induced agranulocytosis: 20 years of clinical observations. ( Connelly, J; Galanello, R; Palmblad, J; Rozova, A; Spino, M; Tricta, F; Uetrecht, J, 2016)
"A risk associated with the iron chelator deferiprone is the development of neutropenia or agranulocytosis."	7.80	Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis. ( Abdel Rahman, Y; Al Damanhouri, G; Al Hawsawi, Z; Al-Tonbary, Y; Badr, M; Elalfy, M; Elsafy, U; Karakas, Z; Kilinc, Y; Qari, M; Salama, M; Shebl, S; Stilman, A; Toiber Temin, N; Tricta, F; Wali, YA; Yazman, D; Yesilipek, MA, 2014)
"One hundred thirteen patients with myelodysplastic syndromes (MDS) with <10% of bone marrow blasts received either deferiprone in a daily dose of 40-90 mg/kg (48 patients) or deferasirox in a daily dose of 10-40 mg/kg (65 patients)."	7.79	A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. ( Belohlavkova, P; Cermak, J; Cervinek, L; Jonasova, A; Neuwirtova, R; Vondrakova, J, 2013)
" Deferiprone is one of a few drugs that are routinely used in medicine for the treatment of iron overload in thalassemic patients."	7.75	Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis. ( Abrol, P; Sen, R; Sharma, RK; Tewari, S, 2009)
" A FA patient started to receive deferiprone (L1) therapy due to iron overload."	7.75	Treatment with deferiprone for iron overload alleviates bone marrow failure in a Fanconi anemia patient. ( Chang, YH; Hsieh, KH; Lu, PJ; Shaw, CF; Su, YN; Wu, KH, 2009)
" The known predisposing factors of infection include prior splenectomy, iron overload and use of iron chelator such as deferoxamine (DFO)."	7.75	Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. ( Chan, GC; Chan, S; Ha, SY; Ho, PL, 2009)
"Variable response to deferiprone has been observed in the management of iron overload in patients with thalassemia major."	7.74	Long-term efficacy of oral deferiprone in management of iron overload in beta thalassemia major. ( Girisha, KM; Goel, H; Phadke, SR, 2008)
"For the past 2-6 years, two groups of thalassemia patients, one of 16 patients on deferoxamine (DFO) monotherapy (35-80 mg/kg, 2-5 days/week) and the other group comprising 19 patients on a deferiprone (L1) and DFO combination therapy (L1 75-100 mg/kg/day and DFO 30-60 mg/kg, 1-5 days/week), have been studied and compared before and after the introduction of the combination therapy."	7.74	Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2008)
"Iron overload is a common complication experienced by transfusion-dependent children with hemoglobin disorders."	7.01	No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis. ( Ahmed, J; Moeed, A; Naeem, U; Rais, H; Saleem, A; Shuja, SH; Waqar, E, 2023)
" No unexpected, serious, or severe adverse events were seen in the ES-DFP group."	6.87	Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial. ( Adly, A; Awad, H; Berdoukas, V; Elalfy, MS; Tarif Salam, M; Tricta, F, 2018)
"DFP/DFX combination proved superior in improving cardiac T2*, treatment compliance, and patients satisfaction with no greater adverse events."	6.80	Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. ( Adly, AM; Elalfy, MS; Elhenawy, YI; Samir, A; Tony, S; Wali, Y, 2015)
"Deferiprone use was associated with a significant decline in mean serum ferritin level from 2532±1463 μg/L at baseline to 2176±1144 μg/L (P<0."	6.75	The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. ( El Alfy, M; El-Beshlawy, A; ElAlfy, MS; Lee, CL; Sari, TT; Tricta, F, 2010)
"Iron overload is the main cause of morbidity and mortality especially from heart failure in patients with beta thalassemia major (TM)."	6.72	Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. ( Daar, S; Pathare, AV, 2006)
" There was no significant difference in the proportion of patients with adverse events in the two therapy groups although the nature of the adverse events differed according to the chelation regimen."	6.72	A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. ( Fischer, R; Galanello, R; Kattamis, A; Ladis, V; Leoni, G; Lund, U; Piga, A; Tricta, F; Voi, V, 2006)
" Selected protocols using DFO, L1, and their combination can be designed for personalized chelation therapy in TI, which can effectively and safely remove all the excess toxic iron and prevent cardiac, liver, and other organ damage."	6.53	Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. ( Kontoghiorghe, CN; Kontoghiorghes, GJ, 2016)
"Deferiprone was more efficacious than DFO in improving cardiac ejection fraction [MD 2."	6.50	A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia. ( Kuo, KH; Mrkobrada, M, 2014)
"This post hoc analysis of the phase 3b/4, randomized, open-label FIRST (Ferriprox in Patients with IRon Overload in Sickle Cell Disease Trial) study (NCT02041299) included patients 17 years and younger with SCD or other anemias receiving deferiprone or deferoxamine."	6.23	Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. ( Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Fradette, C; Hamdy, M; Inusa, B; Kanter, J; Kwiatkowski, JL; Lee, D; Temin, NT; Tricta, F; Veríssimo, MPA; Williams, S, 2024)
"Reversal of arrhythmia to sinus rhythm was noted in all patients."	5.56	Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020)
" The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited."	5.51	Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. ( Adly, AAM; Alshehri, A; Badr, M; Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Hamdy, M; Inusa, B; Kanter, J; Kilinc, Y; Kwiatkowski, JL; Lee, D; Tricta, F; Williams, S, 2022)
"Deferasirox is an oral chelator."	5.46	Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. ( Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F, 2017)
"Iron overload was induced in male ICR mice by injection of iron sucrose (10mg/kg/day) for eight weeks."	5.43	Tetrahydrocurcumin in combination with deferiprone attenuates hypertension, vascular dysfunction, baroreflex dysfunction, and oxidative stress in iron-overloaded mice. ( Donpunha, W; Kukongviriyapan, U; Kukongviriyapan, V; Pakdeechote, P; Sangartit, W; Shibahara, S, 2016)
" Long-term use of L1 resulted in the reduction of the mortality rate in thalassemia patients due to the effective removal of all excess iron from the heart."	5.37	The proceedings of the 19Th international conference on chelation held in London, United Kingdom: major changes in iron chelation therapy in the last 25 years using deferiprone (L1) has resulted in the complete treatment of iron overload. ( Kontoghiorghes, GJ, 2011)
"Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular (LV) function but little is known of their relative effects on the right ventricle (RV), which is being increasingly recognised as an important prognostic factor in cardiomyopathy."	5.37	Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. ( Aessopos, A; Alam, MH; Alpendurada, F; Berdoukas, V; Carpenter, JP; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Roughton, M; Smith, GC; Tanner, MA; Westwood, MA, 2011)
"Five thalassemia major (TM) patients who were undergoing chelation monotherapy with DFO were enrolled."	5.35	Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia. ( Aessopos, A; Assimakopoulos, G; Polonofi, K; Rigaki, K; Tsironi, M, 2008)
"In paediatric patients with transfusion-dependent haemoglobinopathies, deferiprone was effective and safe in inducing control of iron overload during 12 months of treatment."	5.34	Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. ( Bejaoui, M; Bonifazi, D; Ceci, A; Christou, S; Cosmi, C; Cuccia, L; Del Vecchio, GC; Della Pasqua, O; El-Beshlawy, A; Felisi, M; Filosa, A; Hassab, H; Kattamis, A; Kreka, M; Maggio, A; Origa, R; Putti, MC; Reggiardo, G; Sherief, L; Spino, M; Telfer, P; Tempesta, B; Tricta, F; Tsang, YC; Vitrano, A; Zaka, A, 2020)
"Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)."	5.32	Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004)
"Deferiprone is a promising, orally active Fe chelator for the treatment of Fe overload in birds, although its potential side effects need to be considered."	5.32	Clinical evaluation of the oral iron chelator deferiprone for the potential treatment of iron overload in bird species. ( Barker, IK; Conlon, PD; Jacobs, RM; Mehren, KG; Whiteside, DP, 2004)
"An open-label, pilot study was conducted to evaluate deferasirox/deferiprone combination chelation therapy in adult patients with transfusion-dependent thalassemia and severe iron overload."	5.30	Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden. ( Fogel, MA; Hammond, J; Hammond, K; Kokroko, J; Kwiatkowski, JL; Thompson, AA, 2019)
"Three iron chelators are used to treat transfusion-dependent beta-thalassemia: desferrioxamine (DFO), deferasirox (DFX), and deferiprone (DFP)."	5.30	Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study. ( Chen, X; Hsieh, YW; Lin, CH; Peng, CT; Song, TS; Weng, TF; Wu, CC; Wu, KH, 2019)
" Deferiprone (L1) is an EMA- and FDA-approved drug used worldwide for the treatment of iron overload and also other conditions where there are no effective treatments."	5.22	Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology. ( Kontoghiorghes, GJ, 2022)
"was to study the therapeutic value of combined therapy of Deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia with iron overload'."	5.20	Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major. ( Abd El-Lateef, AE; Elfaragy, MS; Elrifaey, SM; Hagag, AA, 2015)
" Here, we used deferiprone (DFP) as an iron chelating agent in TI patients receiving intermittent blood transfusion who are asymptomatic for cardiovascular disease in order to evaluate the effectiveness in iron overload and reduce the possibility of cardiovascular complications."	5.15	Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. ( Akrawinthawong, K; Chaowalit, N; Chatuparisuth, T; Siritanaratkul, N, 2011)
"The prospective, open-label, 1-yr ESCALATOR study in the Middle East was designed to evaluate once-daily deferasirox in patients > or =2 yr with beta-thalassaemia major and iron overload who were previously chelated with deferoxamine and/or deferiprone."	5.14	Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. ( Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Hmissi, A; Kriemler-Krahn, U; Taher, A, 2009)
" In 18 requiring thyroxine supplementation for hypothyroidism, 10 were able to discontinue, and four reduced their thyroxine dose."	5.14	Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. ( Berdoukas, V; Chouliaras, G; Farmaki, K; Pappa, C; Tzoumari, I, 2010)
" Transfusional iron overload in patients with thalassaemia could be reduced to normal body iron range levels using effective deferiprone/deferoxamine combinations."	5.14	Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. ( Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ, 2010)
" The following prospective, randomized trial was carried out to determine the effectiveness, in children and young adults, of combined deferiprone (DFP) and deferoxamine (DFO) in reducing transfusional iron overload compared to either drug alone and to assess the safety and tolerability of DFP."	5.13	Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. ( El-Beshlawy, A; Eltagui, M; Hamdy, M; Hoffbrand, AV; Manz, C; Mostafa, A; Naja, M; Shaker, O; Sharaf, I; Sobh, H; Taher, A; Tarabishi, C; Youssry, I, 2008)
"Oral deferiprone (L1) appears to be promising in the treatment of beta-thalassemia major (TM) patients."	5.12	Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. ( Capra, M; Cracolici, E; De Marchi, D; Lombardi, M; Maggio, A; Malizia, R; Midiri, M; Pepe, A; Positano, V; Prossomariti, L, 2006)
" We compared the efficacy of oral deferiprone (L1) to subcutaneous desferrioxamine (DFO) chelation therapy for the prevention of major endocrinopathies (growth hormone insufficiency, diabetes mellitus and gonadal dysfunction) among patients with beta-thal major to see if we could offer these patients an easier and more painless way to reduce their body iron load and related endocrine complications."	5.12	Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. ( Peng, CT; Tsai, CH; Tsai, FJ; Wang, CH; Wu, KH, 2006)
"Deferiprone is a bidentate oral iron chelator used for the treatment of transfusional iron overload in people."	5.12	Pharmacokinetic disposition of the oral iron chelator deferiprone in the white leghorn chicken. ( Barker, IK; Conlon, PD; Jacobs, RM; Mehren, KG; Spino, M; Tesoro, A; Thiessen, JJ; Whiteside, DP, 2007)
"Deferiprone is a bidentate oral iron chelator used for the treatment of iron overload in people."	5.12	Pharmacokinetic disposition of the oral iron chelator deferiprone in the domestic pigeon (Columba livia). ( Barker, IK; Conlon, PD; Jacobs, RM; Mehren, KG; Spino, M; Tesoro, A; Thiessen, JJ; Whiteside, DP, 2007)
" We characterized NTBI's susceptibility to deferoxamine (directly chelatable iron [DCI]) and redox activity (labile plasma iron [LPI]) during the course of long-term, continuous L1 (deferiprone) treatment of patients with hemoglobin E disease and beta-thalassemia (n = 17)."	5.11	Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. ( Breuer, W; Cabantchik, ZI; Hershko, C; Pootrakul, P; Sametband, M; Sirankapracha, P, 2004)
"Deferiprone is a safe and effective oral iron-chelating agent which can be used, under strict supervision, in transfusion-dependent iron overloaded children."	5.09	A trial of deferiprone in transfusion-dependent iron overloaded children. ( De Silva, DD; Fernandopulle, M; Fonseka, EA; Lucas, GN; Perera, BJ, 2000)
"Deferiprone is an orally active iron-chelating agent that is being evaluated as a treatment for iron overload in thalassemia major."	5.08	Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. ( Brittenham, GM; Burt, AD; Cameron, RG; Fleming, KA; McClelland, RA; McLaren, CE; Olivieri, NF; Templeton, DM, 1998)
"To compare the efficacy and safety of desferrioxamine (DFO), deferiprone (DFP), deferasirox (DFX) and silymarin in patients with either thalassemia or sickle cell disorder through network meta-analysis."	4.98	Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. ( Sivaramakrishnan, G; Sridharan, K, 2018)
" Deferiprone is an oral iron chelator approved for use in the United States as a second line agent for the treatment of transfusional iron overload in patients with thalassemia."	4.95	Deferiprone for the treatment of transfusional iron overload in thalassemia. ( Belmont, A; Kwiatkowski, JL, 2017)
"To assess the effectiveness and safety of oral deferasirox in people with thalassaemia and iron overload."	4.95	Deferasirox for managing iron overload in people with thalassaemia. ( Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK, 2017)
"Iron chelating agents - deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX) - are used to treat chronic iron overload in patients with β-thalassemia in an attempt to reduce morbidity and mortality related to siderosis."	4.93	Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia. ( El Rassi, F; Saliba, AN; Taher, AT, 2016)
" Despite that many chelators inhibit FRD in vitro and in vivo, only Deferiprone (L1) has been shown to be effective and safe in the reversal of oxidative stress related tissue damage in iron overload and other conditions such as cardiomyopathy, acute kidney disease, Friedreich ataxia etc."	4.90	Antioxidant targeting by deferiprone in diseases related to oxidative damage. ( Kolnagou, A; Kontoghiorghe, CN; Kontoghiorghes, GJ, 2014)
"Desferrioxamine is the recommended first-line therapy for iron overload in people with thalassaemia major and deferiprone or deferasirox are indicated for treating iron overload when desferrioxamine is contraindicated or inadequate."	4.89	Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. ( Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ, 2013)
"In the absence of data from randomised controlled trials, there is no evidence to suggest the need for a change in current treatment recommendations; namely that deferiprone is indicated for treating iron overload in people with thalassaemia major when desferrioxamine is contraindicated or inadequate."	4.89	Oral deferiprone for iron chelation in people with thalassaemia. ( Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ, 2013)
"Deferoxamine (DFO) was the standard of care for transfusional iron overload for >40 years, requiring subcutaneous infusion for 8-12 h/day, 5-7 days/week."	4.85	Oral iron chelators. ( Cappellini, MD; Pattoneri, P, 2009)
"We found no reason to change current treatment recommendations, namely deferiprone is indicated for treating iron overload in people with thalassaemia major when desferrioxamine is contraindicated or inadequate."	4.84	Oral deferiprone for iron chelation in people with thalassaemia. ( Brunskill, SJ; Doree, C; Howard, J; Hyde, CJ; Roberts, DJ; Williams, S, 2007)
"The iron chelators deferoxamine (DFO) and deferiprone (L1) have demonstrated their ability to normalize cardiac function in patients with iron overload-induced cardiac disease."	4.84	Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. ( Peng, CT; Tsai, CH; Wu, KH, 2008)
"For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation."	4.83	Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. ( Neufeld, EJ, 2006)
"Iron mobilization from transferrin is one of the most important screening methods for the selection of chelators intended for clinical use in the treatment of iron overload in thalassemia and other conditions."	4.83	Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. ( Kontoghiorghes, GJ, 2006)
"Deferiprone (L1), and appropriate combinations with deferoxamine (DFO), can be used effectively for the treatment of thalassemia and other transfusional iron loading conditions."	4.83	Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. ( Kontoghiorghes, GJ, 2006)
" As LPI is detected primarily in patients with transfusional iron overload and other forms of hemosiderosis, we review here regimens of iron chelation with deferrioxamine and deferiprone (separately or combined) in terms of their efficacy in minimizing daily exposure to LPI in thalassemia major and thalassemia intermedia patients."	4.82	LPI-labile plasma iron in iron overload. ( Breuer, W; Cabantchik, ZI; Cianciulli, P; Zanninelli, G, 2005)
"Therapy with either deferiprone (DFP) or deferoxamine (DFO) is inadequate in achieving negative iron balance in many patients with thalassemia."	4.82	Combined therapy with deferoxamine and deferiprone. ( Kattamis, A, 2005)
"In patients with thalassemia, the assessment of liver iron concentration (LIC) can be used to initiate chelation treatment with desferrioxamine (DFO), deferiprone (DFP), or novel chelators (deferasirox); to adjust chelation dose according to the actual blood transfusion rate; and to monitor chelation efficacy."	4.82	Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. ( Fischer, R; Harmatz, P; Nielsen, P; Piga, A, 2005)
"To summarize efficacy and effectiveness in iron overloaded patients treated with the orally active iron chelator deferiprone also known as L1 or, using meta-analysis of the literature."	4.80	Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). ( Addis, A; Einarson, TR; Koren, G; Loebstein, R, 1999)
" Iron removal in transfusional iron overload is achieved using chelation therapy with the chelating drugs deferoxamine (DF) and deferiprone (L1)."	4.80	Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). ( Hadjigavriel, M; Kolnagou, A; Kontoghiorghes, GJ; Pattichi, K, 2000)
"Deferiprone is the most widely studied oral iron chelator and, at present, the only one shown to be effective in achieving negative iron balance in long-term clinical trials for chronic iron overload."	4.79	Oral iron chelation with deferiprone. ( Diav-Citrin, O; Koren, G, 1997)
"Data from several trials have provided evidence for the efficacy of deferiprone in the treatment of iron overload in thalassemia major."	4.79	Orally active iron chelators in the treatment of iron overload. ( Olivieri, NF, 1996)
" In this report, we describe two pediatric patients diagnosed with nephrolithiasis while undergoing treatment with the chelating agents deferasirox, deferiprone, and deferoxamine for iron overload secondary to repeat blood transfusion."	4.31	Nephrolithiasis in two patients on iron chelation therapy: A case report. ( Baker, Z; Dillon, H; Pena, A; Sparks, S; Syed, H; Wang, Y, 2023)
" The report by Lecornec and colleagues offers useful details on indications and the management of deferiprone, a highly efficient chelator in removing excess cardiac iron but associated with a high risk of agranulocytosis in DBA patients."	4.12	Diamond-Blackfan anaemia with iron overload: A serious issue. ( Fagioli, F; Quarello, P; Ramenghi, U, 2022)
"Iron-overload leads to gut dysbiosis/inflammation and disturbance of metabolites, and deferiprone alleviates those conditions more effectively in WT than in those that are thalassemic."	4.12	Deferiprone has less benefits on gut microbiota and metabolites in high iron-diet induced iron overload thalassemic mice than in iron overload wild-type mice: A preclinical study. ( Buddhasiri, S; Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kittichotirat, W; Kumfu, S; Nawara, W; Sarichai, P; Sriwichaiin, S; Thiennimitr, P; Thonusin, C, 2022)
" Children with thalassemia between 2 and 18 y of age with serum ferritin above 1500 ng/ml were started on oral deferiprone and deferasirox."	4.02	Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study. ( Delhikumar, CG; DivakarJose, RR; Ram Kumar, G, 2021)
"Deferasirox is an orally active, lipophilic iron chelating drug used on thousands of patients worldwide for the treatment of transfusional iron overload."	4.02	Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone. ( Kichigina, LA; Kontoghiorghes, GJ; Polyakov, NE; Selyutina, OY; Timoshnikov, VA, 2021)
"Deferoxamine, deferiprone, and deferasirox are used for the treatment of systemic iron overload, although they possess limitations due to lack of oral activity, lower efficacy, and side effects."	3.96	CN128: A New Orally Active Hydroxypyridinone Iron Chelator. ( Brown, K; Chen, W; Du, H; Hider, RC; Jiang, H; Kong, S; Kong, X; Li, Z; Liu, Z; Lu, Z; Nandi, M; Pan, X; Yu, Y; Yuan, X; Zhang, G, 2020)
"Iron overload, resulting from blood transfusions in patients with chronic anemias, has historically been controlled with regular deferoxamine, but its parenteral requirement encouraged studies of orally-active agents, including deferasirox and deferiprone."	3.91	Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. ( Gallie, BL; Olivieri, NF; Sabouhanian, A, 2019)
"The present study failed to demonstrate that the use of deferiprone at >90 mg/kg/d was associated with increased risk of agranulocytosis or neutropenia, but did demonstrate more effective liver iron control in iron overload patients."	3.91	Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload. ( Binding, A; Kuo, KHM; Tomlinson, G; Ward, R, 2019)
"A 20-year-old male affected by transfusion-dependent β-thalassemia (β-thal), was prescribed intensive chelation therapy with deferoxamine (DFO) and deferiprone (DFP) because of severe hepatic and cardiac iron overload and β-blocker and warfarin to manage a previous event of atrial fibrillation (AFib) and heart failure."	3.88	Life-Threatening Drug-Induced Liver Injury in a Patient with β-Thalassemia Major and Severe Iron Overload on Polypharmacy. ( Casale, M; Cerasari, G; Corvino, F; Perrotta, S; Persico, M; Picariello, S; Rossi, F; Scianguetta, S, 2018)
"Data on the use of deferiprone in young children with iron overload are limited."	3.83	Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience. ( Chuansumrit, A; Kadegasem, P; Sasanakul, W; Sirachainan, N; Songdej, D; Wongwerawattanakoon, P, 2016)
"In this study, we compared the long-term effects of different iron chelation regimens (deferoxamine, deferiprone, deferoxamine + deferiprone, and deferasirox) in preventing or reversing endocrinopathy (diabetes mellitus, hypothyroidism, or hypogonadism) and bone disease (measured through DEXA) in 165 adults with β-thalassemia major (TM) (mean age 39."	3.83	Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. ( Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V, 2016)
"To compare the efficacy and safety of oral iron chelators (Deferiprone and Deferasirox) when used singly and in combination in multi-transfused children with thalassemia."	3.83	Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia. ( Gomber, S; Jain, P; Narang, M; Sharma, S, 2016)
"Use of the iron chelator deferiprone for treatment of iron overload in thalassemia patients is associated with concerns over agranulocytosis, which requires weekly absolute neutrophil counts (ANC)."	3.83	Deferiprone-induced agranulocytosis: 20 years of clinical observations. ( Connelly, J; Galanello, R; Palmblad, J; Rozova, A; Spino, M; Tricta, F; Uetrecht, J, 2016)
"A risk associated with the iron chelator deferiprone is the development of neutropenia or agranulocytosis."	3.80	Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis. ( Abdel Rahman, Y; Al Damanhouri, G; Al Hawsawi, Z; Al-Tonbary, Y; Badr, M; Elalfy, M; Elsafy, U; Karakas, Z; Kilinc, Y; Qari, M; Salama, M; Shebl, S; Stilman, A; Toiber Temin, N; Tricta, F; Wali, YA; Yazman, D; Yesilipek, MA, 2014)
" The generic drugs deferiprone, deferoxamine and their combination offer a safer, less expensive and complete treatment of iron overload in thalassaemia and other iron loading conditions."	3.79	A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? ( Kontoghiorghes, GJ, 2013)
"One hundred thirteen patients with myelodysplastic syndromes (MDS) with <10% of bone marrow blasts received either deferiprone in a daily dose of 40-90 mg/kg (48 patients) or deferasirox in a daily dose of 10-40 mg/kg (65 patients)."	3.79	A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. ( Belohlavkova, P; Cermak, J; Cervinek, L; Jonasova, A; Neuwirtova, R; Vondrakova, J, 2013)
"Deferiprone is used as a chelation agent in chronic iron overload in β-thalassemia patients."	3.79	Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients. ( Dadheech, S; Hussien, MD; Jain, S; Jyothy, A; Munshi, A; Rao, AV; Shaheen, U, 2013)
" The complete treatment of transfusional iron overload in thalassaemia using the deferiprone (L1) and deferoxamine combination is a paradigm to be followed in the treatment of many other metal toxicity conditions."	3.79	The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies. ( Kontoghiorghes, GJ, 2013)
"The iron chelation therapy drugs desferrioxamine B (DFO) and deferiprone (DFP) are used to treat iron overload patients, but not much is known about their adverse effects on other essential metals in vivo."	3.76	Removal of Fe3+ and Zn2+ from plasma metalloproteins by iron chelating therapeutics depicted with SEC-ICP-AES. ( Gailer, J; Sooriyaarachchi, M, 2010)
"In iron overload conditions, plasma contains non-transferrin bound iron species, collectively referred to as plasma NTBI."	3.76	Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. ( Eccleston, J; Evans, P; Hider, RC; Kayyali, R; Porter, JB, 2010)
"Since deferoxamine (DFO), a standard iron-chelating agent that is widely used in patients with iron overload such as hemochromatosis or thalassemia, is a kind of hydroxamine siderophore of Streptomyces species, it can accelerate the in vitro growth of ferophilic organisms such as Vibrio vulnificus, Yersinia enterocolitica, and Mucorales."	3.75	Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus. ( Kim, DM; Neupane, GP, 2009)
" Deferiprone is one of a few drugs that are routinely used in medicine for the treatment of iron overload in thalassemic patients."	3.75	Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis. ( Abrol, P; Sen, R; Sharma, RK; Tewari, S, 2009)
" The introduction of effective chelation therapy protocols using primarily deferiprone (L1) in combination with deferoxamine (DFO) resulted in the reduction of iron overload induced cardiac failures, which is the main cause of death in thalassemia major."	3.75	Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications. ( Kolnagou, A; Kontoghiorghes, GJ, 2009)
"Our previous study showed that combined therapy with deferiprone (L1) and deferoxamine (DFO) was safe and efficacious in reducing iron overload in poorly-chelated thalassemia major patients for the short-term but the magnetic resonance imaging (MRI) T2* evaluation was not available at that time."	3.75	A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*. ( Chan, GC; Cheuk, DK; Chiang, AK; Chu, WC; Ha, SY; Ho, MH; Mok, AS; Raskalkar, DD, 2009)
" A FA patient started to receive deferiprone (L1) therapy due to iron overload."	3.75	Treatment with deferiprone for iron overload alleviates bone marrow failure in a Fanconi anemia patient. ( Chang, YH; Hsieh, KH; Lu, PJ; Shaw, CF; Su, YN; Wu, KH, 2009)
" The known predisposing factors of infection include prior splenectomy, iron overload and use of iron chelator such as deferoxamine (DFO)."	3.75	Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. ( Chan, GC; Chan, S; Ha, SY; Ho, PL, 2009)
"Variable response to deferiprone has been observed in the management of iron overload in patients with thalassemia major."	3.74	Long-term efficacy of oral deferiprone in management of iron overload in beta thalassemia major. ( Girisha, KM; Goel, H; Phadke, SR, 2008)
" Desferrioxamine (DFO) (Desferal; Novartis, Switzerland) and Deferiprone (Ferriprox; Apotex, Canada) are ICTs used to treat iron overload."	3.74	Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. ( Abetz, L; Baladi, JF; Desrosiers, MP; Ishak, K; Lordan, N; Payne, KA; Proskorovsky, I; Rofail, D; Viala, M, 2008)
" However, other factors may also have similar effects such as the level of iron overload, chronic immuno-stimulation due to transfusions, splenectomy and deferoxamine (DFO)."	3.74	Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment. ( Athanassiou-Metaxa, M; Economou, M; Kanakoudi-Tsakalidou, F; Perifanis, V; Taparkou, A; Tourkantoni, N; Tzimouli, V; Zafiriou, D, 2008)
"For the past 2-6 years, two groups of thalassemia patients, one of 16 patients on deferoxamine (DFO) monotherapy (35-80 mg/kg, 2-5 days/week) and the other group comprising 19 patients on a deferiprone (L1) and DFO combination therapy (L1 75-100 mg/kg/day and DFO 30-60 mg/kg, 1-5 days/week), have been studied and compared before and after the introduction of the combination therapy."	3.74	Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2008)
"New measures of iron accumulation in liver and heart (superconducting quantum inference device and magnetic resonance imaging), and oral iron chelators (deferiprone and deferasirox) are available for managing iron overload in thalassemia major."	3.74	Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. ( Angelucci, E; Barosi, G; Camaschella, C; Cappellini, MD; Cazzola, M; Galanello, R; Marchetti, M; Piga, A; Tura, S, 2008)
"We used combined therapy with desferrioxamine and deferiprone to treat 79 patients with severe iron overload (serum ferritin higher than 3000 ng/mL) who had low compliance with subcutaneous desferrioxamine."	3.73	Combined therapy with deferiprone and desferrioxamine in thalassemia major. ( Agus, A; Bina, P; Crobu, G; Defraia, E; Dessì, C; Galanello, R; Leoni, G; Muroni, PP; Origa, R, 2005)
"Deferiprone (L1) is an orally active iron-chelation agent that is being evaluated as a treatment for iron overload in thalassemia major."	3.73	Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. ( Peng, CT; Tsai, CH; Wu, KH; Wu, SF, 2006)
"Although the beneficial effects of deferoxamine (DFO) on iron-associated morbidity and mortality are well documented, the role of deferiprone (L1) in the management of transfusional iron overload is controversial."	3.71	The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. ( Hershko, C; Huerta, M; Konijn, AM; Link, G; Reinus, C; Rosenmann, E, 2002)
"In iron overload, non-transferrin-bound iron (NTBI) is found in plasma and is rapidly removed by hepatocytes."	3.69	Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non-transferrin-bound iron in rats. ( Arnaud, J; Bolder, U; Brissot, P; Hofmann, AF; Schteingart, CD, 1997)
"Deferiprone (Ferriprox®) is an oral iron chelator indicated for the treatment of transfusional iron overload due to thalassemia syndromes and has been recently approved as a treatment for iron overload in adult and pediatric patients with SCD and other anemias."	3.11	The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease. ( Fradette, C; Mercier-Ross, J; Rozova, A; Soulières, D; Tricta, F; Tsang, YC, 2022)
"Iron overload is a common complication experienced by transfusion-dependent children with hemoglobin disorders."	3.01	No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis. ( Ahmed, J; Moeed, A; Naeem, U; Rais, H; Saleem, A; Shuja, SH; Waqar, E, 2023)
"Iron overload is a pathological condition resulting from a congenital impairment of its regulation, increased intestinal iron absorption secondary to bone marrow erythroid hyperplasia, or a chronic transfusional regimen."	3.01	Iron chelation therapy. ( Bova, C; Bruzzese, A; Capodanno, I; Filippelli, G; Gentile, M; Lucia, E; Martino, EA; Mendicino, F; Morabito, F; Neri, A; Olivito, V; Vigna, E, 2023)
"The maltol-iron complex is a recently approved drug used for increasing iron intake in the treatment of iron deficiency anemia, a condition affecting one-third to one-quarter of the world's population."	3.01	Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects. ( Kontoghiorghes, GJ, 2023)
" In principle, iron chelators can be combined with an infinite number of dosing regimens; these involve simultaneous or sequential exposure to the chelators on the same day or alternating the drugs on different days."	3.01	Combination chelation therapy. ( Aydinok, Y, 2023)
" No unexpected, serious, or severe adverse events were seen in the ES-DFP group."	2.87	Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial. ( Adly, A; Awad, H; Berdoukas, V; Elalfy, MS; Tarif Salam, M; Tricta, F, 2018)
" In this context, the use of curcumin, a dietary phytochemical derived from turmeric, as a natural and safe antioxidant with iron-chelating activity may be a useful strategy for the management of iron overload."	2.82	Protective Effects of Curcumin against Iron-induced Toxicity. ( Barati, M; Iranshahy, M; Moinipour, N; Sahebkar, A; Shakeri, A, 2022)
"DFP/DFX combination proved superior in improving cardiac T2*, treatment compliance, and patients satisfaction with no greater adverse events."	2.80	Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. ( Adly, AM; Elalfy, MS; Elhenawy, YI; Samir, A; Tony, S; Wali, Y, 2015)
"Neutropenia and agranulocytosis were also detected, suggesting needing of strict hematological control."	2.80	Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial. ( Calvaruso, G; Colletta, G; Di Maggio, R; Gerardi, C; Lai, E; Maggio, A; Pitrolo, L; Quota, A; Rigoli, LC; Sacco, M; Vitrano, A, 2015)
" Incidence of adverse effects was comparable to that in thalassemic patients."	2.76	Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. ( Cermak, J; Hochova, I; Jonasova, A; Neuwirtova, R; Siskova, M; Vondrakova, J; Walterova, L, 2011)
"We evaluated 36 patients affected by thalassemia major treated with combined chelation therapy."	2.75	Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study. ( Ammirabile, M; Cinque, P; Costantini, S; Di Matola, T; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A, 2010)
"Deferiprone use was associated with a significant decline in mean serum ferritin level from 2532±1463 μg/L at baseline to 2176±1144 μg/L (P<0."	2.75	The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. ( El Alfy, M; El-Beshlawy, A; ElAlfy, MS; Lee, CL; Sari, TT; Tricta, F, 2010)
"Iron overload is the main cause of morbidity and mortality especially from heart failure in patients with beta thalassemia major (TM)."	2.72	Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. ( Daar, S; Pathare, AV, 2006)
" We conclude that the short-term use of L1, with or without DFO, was safe and efficacious in our Chinese patient cohort."	2.72	A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. ( Chan, GC; Chik, KW; Ha, SY; Lam, CW; Lee, AC; Ling, SC; Luk, CW; Ng, IO, 2006)
" There was no significant difference in the proportion of patients with adverse events in the two therapy groups although the nature of the adverse events differed according to the chelation regimen."	2.72	A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. ( Fischer, R; Galanello, R; Kattamis, A; Ladis, V; Leoni, G; Lund, U; Piga, A; Tricta, F; Voi, V, 2006)
"Deferiprone was given at a dose of 75 mg/kg daily for 12 months."	2.71	Deferiprone as an oral iron chelator in sickle cell disease. ( Douskou, M; Loukopoulos, D; Meletis, J; Ourailidis, A; Papassotiriou, I; Stamoulakatou, A; Terpos, E; Voskaridou, E, 2005)
" Selected protocols using DFO, L1, and their combination can be designed for personalized chelation therapy in TI, which can effectively and safely remove all the excess toxic iron and prevent cardiac, liver, and other organ damage."	2.53	Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. ( Kontoghiorghe, CN; Kontoghiorghes, GJ, 2016)
"Deferiprone was more efficacious than DFO in improving cardiac ejection fraction [MD 2."	2.50	A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia. ( Kuo, KH; Mrkobrada, M, 2014)
"Iron overload is one of the major causes of morbidity and death in patients undergoing chronic transfusion therapy."	2.48	Iron chelation therapy in the management of transfusion-related cardiac iron overload. ( Fernandes, JL, 2012)
"Iron overload has many different causes, both genetic and environmental."	2.48	Iron mobilization using chelation and phlebotomy. ( Aaseth, J; Andersen, O; Flaten, TP; Kontoghiorghes, GJ, 2012)
"Iron overload is frequently observed in patients with hematologic diseases before and after allogeneic stem-cell transplantation because they usually receive multiple red blood cell transfusions."	2.47	Iron overload and allogeneic hematopoietic stem-cell transplantation. ( Chao, NJ; Kanda, J; Kawabata, H, 2011)
"Deferasirox has been identified to cause fatal gastrointestinal hemorrhages, renal tubulopathy, hepatic and renal failure, alopecia and anaphylactic reactions in addition to previously reported fatal or serious toxic side effects such as agranulocytosis, renal and hepatic toxicity, skin rash and gastric intolerance."	2.46	Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. ( Kontoghiorghes, GJ, 2010)
"Iron overload is a major cause of morbidity and mortality in transfusion-dependent anemias."	2.46	An update on disordered iron metabolism and iron overload. ( Ward, R, 2010)
"Monitoring of iron overload has advanced with the increasing use of MRI techniques to estimate iron balance (changes in liver iron concentration) and extrahepatic iron distribution (myocardial T2*)."	2.46	Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. ( Porter, JB; Shah, FT, 2010)
"Iron overload is characterized by excessive iron deposition and consequent injury and dysfunction of the heart, liver, anterior pituitary, pancreas, and joints."	2.44	Chelation therapy for iron overload. ( Barton, JC, 2007)
"deferoxamine treatment than combined treatment with deferiprone and deferoxamine."	2.44	Light and shadows in the iron chelation treatment of haematological diseases. ( Maggio, A, 2007)
"Deferiprone is a three-times-daily oral iron chelator, but has limited availability in the United States."	2.44	Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. ( Baladi, JF; Coates, TD; Delea, TE; Edelsberg, J; Phatak, PD; Sofrygin, O; Thomas, SK, 2007)
"Deferasirox is an oral iron-chelating agent with favorable pharmacokinetics, including a long half-life allowing continuous 24-hour chelation with once-daily dosing."	2.44	Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. ( Goldberg, SL, 2007)
"If untreated, iron overload is responsible for heart, liver and endocrine diseases."	2.42	Pharmacotherapy of iron overload in thalassaemic patients. ( Ceci, A; De Mattia, D; De Sanctis, V; Felisi, M, 2003)
"Deferiprone (L1; CP20) is an orally absorbed bidentate hydroxypyridinone iron chelator that can induce urinary iron excretion, promote negative iron balance and reduce hepatic iron levels in some transfusion-dependent patients, particularly in those who are markedly iron overloaded and have not received regular deferoxamine therapy."	2.40	A risk-benefit assessment of iron-chelation therapy. ( Porter, JB, 1997)
"Deferiprone treatment tended to decrease muscle iron levels in mdx mice (-30%, P < 0."	1.72	Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy. ( Alves, FM; Ayton, S; Bush, AI; Caldow, MK; Chung, JD; Crouch, PJ; Hardee, JP; Hare, DJ; Koopman, R; Kysenius, K; Lynch, GS; Trieu, J, 2022)
"Management of beta-thalassemia major (TM) requires life-long hemotransfusions leading to iron overload."	1.56	Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities. ( Georgiev, PG; Goranov, SE; Goranova-Marinova, VS; Sapunarova, KG, 2020)
"Treatment with deferiprone of UROS-deficient erythroid cell lines and peripheral blood CD34+-derived erythroid cultures from a patient with CEP inhibited iron-dependent protein ALAS2 and iron-responsive element-binding protein 2 expression and reduced porphyrin production."	1.56	Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria. ( Bedel, A; Blouin, JM; Costet, P; Daher, R; Ged, C; Gouya, L; Karim, Z; Lalanne, M; Lamrissi-Garcia, I; Moreau-Gaudry, F; Morice-Picard, F; Puy, H; Richard, E, 2020)
"Reversal of arrhythmia to sinus rhythm was noted in all patients."	1.56	Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020)
"Brain iron overload is chronic and slow progressing and plays an important role in the pathogenesis of neurodegenerative disorders."	1.51	MRI imaging and histopathological study of brain iron overload of β-thalassemic mice. ( Fucharoen, S; Huaijantug, S; Morales, NP; Svasti, S; Teerapan, W; Yatmark, P, 2019)
"Deferiprone was the most effective chelator to improve glucose homeostasis in chronically transfused thalassemics."	1.48	Glucose Homeostasis and Effect of Chelation on β Cell Function in Children With β-Thalassemia Major. ( Bagmar, S; Dabas, A; Gomber, S; Madhu, SV, 2018)
"Deferasirox monotherapy was less effective than deferiprone in improving myocardial siderosis and biventricular function and less effective than desferrioxamine in improving the LVEF."	1.48	MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine. ( Allò, M; Cuccia, L; D'Ascola, DG; Gamberini, MR; Lisi, R; Mangione, M; Meloni, A; Pepe, A; Pistoia, L; Positano, V; Restaino, G; Ricchi, P; Righi, R; Rosso, R; Spasiano, A, 2018)
"Diabetes mellitus is a common endocrinopathy in patients with β-thalassaemia major (β-TM), which is high prevalent in southern China."	1.46	Prevalence of diabetes mellitus in Chinese children with thalassaemia major. ( Bajoria, R; Chatterjee, R; Jiang, Y; Lai, Y; Liang, Y; Pan, H; Su, H; Xia, N, 2017)
"Deferasirox is an oral chelator."	1.46	Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. ( Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F, 2017)
"Cardiac iron overload was induced to a greater extent than in a previous study by feeding the mice with an iron-enriched diet for 4 months."	1.43	Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. ( Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S, 2016)
"Iron chelators are used to treat iron overload cardiomyopathy patients."	1.43	Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats. ( Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Khamseekaew, J; Kumfu, S; Srichairatanakool, S; Sripetchwandee, J; Wongjaikam, S, 2016)
"Iron overload was induced in male ICR mice by injection of iron sucrose (10mg/kg/day) for eight weeks."	1.43	Tetrahydrocurcumin in combination with deferiprone attenuates hypertension, vascular dysfunction, baroreflex dysfunction, and oxidative stress in iron-overloaded mice. ( Donpunha, W; Kukongviriyapan, U; Kukongviriyapan, V; Pakdeechote, P; Sangartit, W; Shibahara, S, 2016)
"Patients with thalassemia major become transfusion- dependent with subsequent iron overload."	1.42	Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload. ( Hagag, AA; Hamam, MA; Hazaa, SM; Taha, OA, 2015)
"Pulmonary iron overload was induced in heterozygous β-globin knockout mice (muβth-3/+, BKO)."	1.42	Effects of Iron Chelators on Pulmonary Iron Overload and Oxidative Stress in β-Thalassemic Mice. ( Chaisri, U; Fucharoen, S; Hemstapat, W; Morales, NP; Srichairatanakool, S; Svasti, S; Wichaiyo, S; Yatmark, P, 2015)
"Deferiprone (20·6%) was less commonly prescribed in patients with elevated alanine aminotransferase; while a deferoxamine + deferiprone combination (17·9%) was more commonly used in patients with serum ferritin >2500 ng/ml or CMR T2* <20 ms."	1.39	Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project. ( Cappellini, MD; Caruso, V; Chiavilli, F; Commendatore, F; Forni, GL; Galanello, R; Longo, F; Mulas, S; Musallam, KM; Piga, A; Quarta, G, 2013)
"Deferiprone, because of its lower molecular weight, might cross into heart mitochondria more efficiently, improving their activity and, thereby, myocardial cell function."	1.39	Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major. ( Barone, R; Calvaruso, G; Campisi, S; Capra, M; Caruso, V; Casale, M; Ciancio, A; Cianciulli, P; Cuccia, L; D'Ascola, G; Filosa, A; Gagliardotto, F; Gerardi, C; Maggio, A; Pitrolo, L; Prossomariti, L; Rigano, P; Rizzo, M; Vitrano, A, 2013)
"Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron."	1.37	Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. ( Bisconte, MG; Capra, M; Caruso, V; Cianciulli, P; Filosa, A; Lippi, A; Lombardi, M; Maggio, A; Malaventura, C; Meloni, A; Midiri, M; Missere, M; Pepe, A; Pitrolo, L; Positano, V; Prossomariti, L; Putti, MC; Quarta, A; Romeo, MA; Rossi, G, 2011)
"Deferiprone has been shown to be capable of reducing the iron burden in patients with β-thalassaemia."	1.37	Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status. ( Chantharaksri, U; Fucharoen, S; Jirasomprasert, T; Jittangprasert, P; Limenta, LM; Morales, NP; Wilairat, P; Yamanont, P, 2011)
"Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular (LV) function but little is known of their relative effects on the right ventricle (RV), which is being increasingly recognised as an important prognostic factor in cardiomyopathy."	1.37	Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. ( Aessopos, A; Alam, MH; Alpendurada, F; Berdoukas, V; Carpenter, JP; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Roughton, M; Smith, GC; Tanner, MA; Westwood, MA, 2011)
"For chronic conditions such as thalassemia major, even when oral chelation therapy is available, support by an integrated team including a clinical psychologist and nurse specialist working with the treatment center is recommended to achieve optimal results."	1.37	Challenges of adherence and persistence with iron chelation therapy. ( El-Beshlawy, A; Evangeli, M; Porter, JB, 2011)
"Deferiprone (L1) has been used in several countries for iron chelation therapy for over one decade."	1.36	Long-term response to deferiprone therapy in Asian Indians. ( Das, RR; Marwaha, RK; Panigrahi, I, 2010)
"Iron overload is known to exacerbate many infectious diseases."	1.36	The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies. ( Kolnagou, A; Kontoghiorghes, GJ; Petrikkos, G; Skiada, A, 2010)
"The risk of cardiac death during 1990-1999 and 2000-2008 was compared."	1.36	Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. ( Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K, 2010)
"Myocardial iron overload is the leading cause of death in patients with beta-thalassemia major."	1.36	Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. ( Bina, P; Carta, MP; Cianciulli, P; Farci, P; Galanello, R; Grady, RW; Lai, ME; Maggio, A; Pepe, A; Sau, F; Vacquer, S, 2010)
"Patients with thalassemia major accumulate body iron over time as a consequence of continuous red blood cell transfusions which cause hepatic, endocrine, and cardiac complications."	1.36	Combined iron chelation therapy. ( Agus, A; Campus, S; Danjou, F; Galanello, R; Giardina, PJ; Grady, RW, 2010)
" However, despite these fatalities it would appear that there is no regular monitoring of such toxicities or of effects such as the accumulation of toxic metals."	1.35	Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients. ( Kontoghiorghes, GJ, 2008)
"Five thalassemia major (TM) patients who were undergoing chelation monotherapy with DFO were enrolled."	1.35	Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia. ( Aessopos, A; Assimakopoulos, G; Polonofi, K; Rigaki, K; Tsironi, M, 2008)
"Comprehensive care for thalassemia major (TM) patients has achieved great advances in the world, yet psychosocial developmental aspects of care in families with afflicted members has made only limited progress."	1.33	Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan. ( Kuo, HT; Peng, CT; Tsai, MY; Wu, KH, 2006)
"The parents of 18 thalassemia major patients (under 12 years of age) were interviewed (in two sessions) to determine their feelings, sources of stress, and support during their childrens' disease process."	1.33	Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan. ( Kuo, HT; Peng, CT; Tsai, MY, 2006)
"Deferiprone-treated hearts had greater mass (16."	1.33	Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. ( Aguilar, MI; Gonzalez, I; Moats, R; Nelson, M; Nick, H; Otto-Duessel, M; Shimada, H; Wood, JC, 2006)
"Post transfusionnal iron overload is related to both a degree of RBC units transfused and excess intestinal absorption of Fe related to dyserythopoiesis."	1.33	[Post transfusionnal iron overload]. ( Rose, C, 2006)
"Deferiprone is an iron chelator that has the potential to be more effective than deferoxamine in removing intracellular iron from the heart."	1.32	Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. ( Fogliacco, E; Gaglioti, C; Piga, A; Tricta, F, 2003)
"Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)."	1.32	Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004)
"Deferoxamine was more efficient in removing excess iron from the liver but aggravated the disease related anaemia."	1.32	Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation. ( Arosio, C; Grisoli, M; Mariani, R; Pelucchi, S; Piga, A; Piperno, A; Trombini, P, 2004)
"Deferiprone is a promising, orally active Fe chelator for the treatment of Fe overload in birds, although its potential side effects need to be considered."	1.32	Clinical evaluation of the oral iron chelator deferiprone for the potential treatment of iron overload in bird species. ( Barker, IK; Conlon, PD; Jacobs, RM; Mehren, KG; Whiteside, DP, 2004)

Research

Studies (304)

Authors

Clinical Trials (16)

Trial Overview

Trial Outcomes

Change From Baseline in Cardiac Iron

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	23 (7.57)	18.2507
2000's	118 (38.82)	29.6817
2010's	127 (41.78)	24.3611
2020's	36 (11.84)	2.80

Authors	Studies
Dehkordi, LS	1
Liu, ZD	1
Hider, RC	4
Liu, J	1
Obando, D	1
Schipanski, LG	1
Groebler, LK	1
Witting, PK	1
Kalinowski, DS	1
Richardson, DR	2
Codd, R	1
Chen, W	1
Yuan, X	1
Li, Z	1
Lu, Z	1
Kong, S	1
Jiang, H	1
Du, H	1
Pan, X	1
Nandi, M	1
Kong, X	1
Brown, K	1
Liu, Z	1
Zhang, G	1
Yu, Y	1
Jiang, X	1
Zhou, T	1
Bai, R	1
Xie, Y	1
Moinipour, N	1
Barati, M	1
Sahebkar, A	1
Iranshahy, M	1
Shakeri, A	1
Kwiatkowski, JL	6
Hamdy, M	3
El-Beshlawy, A	7
Ebeid, FSE	2
Badr, M	2
Alshehri, A	1
Kanter, J	2
Inusa, B	2
Adly, AAM	1
Williams, S	3
Kilinc, Y	2
Lee, D	2
Tricta, F	13
Elalfy, MS	6
Badawy, SM	1
Kattamis, A	6
Ezzat, H	1
Deschamps, B	1
Sicard, E	1
Fradette, C	3
Zhao, F	1
Chung Tsang, Y	1
Sheth, S	1
Piga, A	10
Soulières, D	1
Mercier-Ross, J	1
Rozova, A	2
Tsang, YC	2
Alves, FM	1
Kysenius, K	2
Caldow, MK	1
Hardee, JP	1
Chung, JD	1
Trieu, J	1
Hare, DJ	1
Crouch, PJ	2
Ayton, S	1
Bush, AI	1
Lynch, GS	1
Koopman, R	1
Hašková, P	1
Applová, L	1
Jansová, H	1
Homola, P	1
Franz, KJ	1
Vávrová, K	1
Roh, J	1
Šimůnek, T	1
Kontoghiorghes, GJ	35
Lecornec, N	1
Castex, MP	1
Réguerre, Y	1
Moreau, P	1
Marie, I	1
Garçon, L	1
Da Costa, L	1
Leblanc, T	1
Saleem, A	1
Waqar, E	1
Shuja, SH	1
Naeem, U	1
Moeed, A	1
Rais, H	1
Ahmed, J	1
Di Paola, A	1
Tortora, C	1
Argenziano, M	1
Marrapodi, MM	1
Rossi, F	2
Quarello, P	1
Ramenghi, U	1
Fagioli, F	1
Sriwichaiin, S	1
Thiennimitr, P	1
Thonusin, C	1
Sarichai, P	1
Buddhasiri, S	1
Kumfu, S	6
Nawara, W	1
Kittichotirat, W	1
Fucharoen, S	10
Chattipakorn, N	7
Chattipakorn, SC	7
Feng, W	1
Xiao, Y	1
Zhao, C	1
Zhang, Z	1
Liu, W	1
Ma, J	1
Ganz, T	1
Zhang, J	1
Liu, S	1
Bruzzese, A	1
Martino, EA	1
Mendicino, F	1
Lucia, E	1
Olivito, V	1
Bova, C	1
Filippelli, G	1
Capodanno, I	1
Neri, A	1
Morabito, F	1
Gentile, M	1
Vigna, E	1
Lupu, M	1
Coada, CA	1
Tudor, DV	1
Baldea, I	1
Florea, A	1
Toma, VA	1
Lupsor, A	1
Moldovan, R	1
Decea, N	1
Filip, GA	1
Dillon, H	1
Baker, Z	1
Pena, A	1
Wang, Y	1
Syed, H	1
Sparks, S	1
Aydinok, Y	2
Veríssimo, MPA	1
Temin, NT	1
Sumneang, N	1
Khamseekaew, J	4
Siri-Angkul, N	2
Sripetchwandee, J	2
Svasti, S	3
Srichairatanakool, S	6
Pepe, A	5
Meloni, A	3
Filosa, A	4
Pistoia, L	2
Borsellino, Z	1
D'Ascola, DG	2
Lisi, R	2
Putti, MC	4
Allò, M	2
Gamberini, MR	2
Quarta, A	2
Fidone, C	1
Casini, T	1
Restaino, G	2
Midiri, M	3
Mangione, M	2
Positano, V	4
Casale, M	3
Lertsuwan, K	1
Nammultriputtar, K	1
Nanthawuttiphan, S	1
Tannop, N	1
Teerapornpuntakit, J	1
Thongbunchoo, J	1
Charoenphandhu, N	1
Maggio, A	9
Felisi, M	3
Reggiardo, G	1
Bejaoui, M	1
Sherief, L	1
Christou, S	1
Cosmi, C	1
Della Pasqua, O	1
Del Vecchio, GC	2
Cuccia, L	3
Hassab, H	1
Kreka, M	1
Origa, R	3
Spino, M	8
Telfer, P	4
Tempesta, B	1
Vitrano, A	4
Zaka, A	1
Bonifazi, D	2
Ceci, A	3
Daar, S	3
Al Khabori, M	1
Al Rahbi, S	1
Hassan, M	1
El Tigani, A	1
Pennell, DJ	6
DivakarJose, RR	1
Delhikumar, CG	1
Ram Kumar, G	1
Georgiev, PG	1
Sapunarova, KG	1
Goranova-Marinova, VS	1
Goranov, SE	1
Blouin, JM	1
Ged, C	1
Lalanne, M	1
Lamrissi-Garcia, I	1
Morice-Picard, F	1
Costet, P	1
Daher, R	1
Moreau-Gaudry, F	1
Bedel, A	1
Puy, H	1
Gouya, L	1
Karim, Z	1
Richard, E	1
Chuang, TY	1
Li, JP	1
Weng, TF	2
Wu, KH	10
Chao, YH	1
Peyam, S	1
Bansal, D	3
Zardkhoni, SZ	1
Moghaddam, AG	1
Rad, F	1
Ghatee, MA	1
Omidifar, N	1
Ghaedi, M	1
Etemadfar, P	1
Vadolas, J	1
Ng, GZ	1
Dames, S	1
Eisermann, M	1
Nualkaew, T	1
Vilcassim, S	1
Schaeper, U	1
Grigoriadis, G	1
Timoshnikov, VA	1
Kichigina, LA	1
Selyutina, OY	1
Polyakov, NE	1
Kolnagou, A	17
Kontoghiorghe, CN	3
Noureldine, MHA	1
Taher, AT	6
Haydar, AA	1
Berjawi, A	1
Khamashta, MA	1
Uthman, I	1
Belmont, A	1
Liang, Y	1
Bajoria, R	1
Jiang, Y	1
Su, H	1
Pan, H	1
Xia, N	1
Chatterjee, R	1
Lai, Y	1
Bollig, C	1
Schell, LK	1
Rücker, G	1
Allert, R	1
Motschall, E	1
Niemeyer, CM	1
Bassler, D	1
Meerpohl, JJ	1
Botzenhardt, S	1
Wong, ICK	1
Neubert, A	1
Adly, A	1
Awad, H	1
Tarif Salam, M	1
Berdoukas, V	5
Chan, S	2
Lian, Q	1
Chen, MP	1
Jiang, D	1
Ho, JTK	1
Cheung, YF	1
Chan, GC	4
Wong, SA	1
Leitch, HA	1
Elgharabawy, RM	1
Elgharbawy, DM	1
Emara, AM	2
Gomber, S	2
Dabas, A	1
Bagmar, S	1
Madhu, SV	1
Mirlohi, MS	1
Yaghooti, H	1
Shirali, S	1
Aminasnafi, A	1
Olapour, S	1
Karakas, Z	2
Yilmaz, Y	1
Bayramoglu, Z	1
Karaman, S	1
Aydogdu, S	1
Karagenc, AO	1
Tugcu, D	1
Dursun, M	1
Harrington, JM	1
Mysore, MM	1
Crumbliss, AL	1
Sridharan, K	1
Sivaramakrishnan, G	1
Fortin, PM	1
Fisher, SA	3
Madgwick, KV	1
Trivella, M	1
Hopewell, S	1
Doree, C	4
Estcourt, LJ	1
Wahidiyat, PA	1
Yosia, M	1
Sari, TT	2
Pinto, VM	1
Balocco, M	2
Quintino, S	1
Bacigalupo, L	1
Gianesin, B	1
Rizzi, M	1
Malagò, R	1
De Franceschi, L	1
Forni, GL	3
Hammond, J	1
Thompson, AA	1
Fogel, MA	1
Hammond, K	1
Kokroko, J	1
Aggarwal, M	1
Mirgh, S	1
Totadri, S	2
Trehan, A	2
Khadwal, A	1
Bhatia, A	1
Sodhi, KS	1
Bhatia, P	2
Jain, R	1
Das, R	1
Khandelwal, N	1
Picariello, S	1
Corvino, F	1
Cerasari, G	1
Scianguetta, S	1
Persico, M	1
Perrotta, S	1
Rosso, R	1
Spasiano, A	2
Righi, R	1
Ricchi, P	2
Hoffbrand, AV	8
Ghosh, K	2
Olivieri, NF	5
Sabouhanian, A	1
Gallie, BL	1
Lin, CH	1
Chen, X	1
Wu, CC	1
Song, TS	1
Hsieh, YW	1
Peng, CT	10
Binding, A	1
Ward, R	2
Tomlinson, G	1
Kuo, KHM	1
Yatmark, P	2
Huaijantug, S	1
Teerapan, W	1
Morales, NP	3
Chaudhary, K	1
Chilakala, A	1
Ananth, S	1
Mandala, A	1
Veeranan-Karmegam, R	1
Powell, FL	1
Ganapathy, V	1
Gnana-Prakasam, JP	1
Viprakasit, V	2
Nuchprayoon, I	1
Chuansumrit, A	2
Torcharus, K	1
Pongtanakul, B	1
Laothamatas, J	1
Pooliam, J	2
Supajitkasem, S	1
Suriyaphol, P	1
Tanphaichitr, VS	2
Tuchinda, S	1
Mallat, NS	1
Beydoun, A	1
Musallam, KM	5
Koussa, S	3
Longo, F	2
Cappellini, MD	5
Quarta, G	1
Chiavilli, F	1
Commendatore, F	1
Mulas, S	1
Caruso, V	3
Galanello, R	11
Rigano, P	2
Calvaruso, G	3
Barone, R	2
Capra, M	3
Gagliardotto, F	1
Pitrolo, L	3
Prossomariti, L	4
Gerardi, C	2
Campisi, S	1
Cianciulli, P	4
Rizzo, M	1
D'Ascola, G	1
Ciancio, A	1
Brittenham, GM	3
Bentley, A	1
Gillard, S	1
Connelly, J	4
Cermak, J	2
Jonasova, A	2
Vondrakova, J	2
Cervinek, L	1
Belohlavkova, P	1
Neuwirtova, R	2
Brunskill, SJ	3
Gooding, S	2
Chowdhury, O	2
Roberts, DJ	4
Danjou, F	2
Cossa, S	1
Matta, G	1
Bina, P	3
Dessì, C	3
Defraia, E	2
Foschini, ML	1
Leoni, G	3
Morittu, M	1
Dadheech, S	1
Rao, AV	1
Shaheen, U	1
Hussien, MD	1
Jain, S	1
Jyothy, A	1
Munshi, A	1
de Witte, T	1
Jang, JH	1
Lee, JH	1
Yoon, SS	1
Jo, DY	1
Kim, HJ	1
Chung, J	1
Lee, JW	1
Naoum, FA	1
Espósito, BP	1
Ruiz, LP	1
Ruiz, MA	1
Tanaka, PY	1
Sobreira, JT	1
Cançado, RD	1
de Barros, JC	1
Bragadesh, T	1
Bhandari, S	1
Elalfy, M	1
Wali, YA	1
Qari, M	1
Al Damanhouri, G	1
Al-Tonbary, Y	1
Yazman, D	2
Al Hawsawi, Z	1
Yesilipek, MA	1
Elsafy, U	1
Salama, M	1
Abdel Rahman, Y	1
Shebl, S	1
Stilman, A	1
Toiber Temin, N	1
Merkel, DG	1
Nagler, A	1
Di Maggio, R	2
Ballas, S	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias[NCT02041299]	Phase 4	230 participants (Actual)	Interventional	2014-04-17	Terminated (stopped due to Difficulties with additional recruitment as pool of potential patients was exhausted, and sufficient information for determination of study outcome measure was already obtained)
The Pharmacokinetic Profile of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease[NCT01835496]	Phase 1	8 participants (Actual)	Interventional	2013-05-31	Completed
Multicentre, Randomised, Open Label, Non-inferiority Trial to Evaluate the Efficacy and Safety of Deferiprone Compared to Deferasirox in Patients Aged From 1 Month to Less Than 18 Years Affected by Transfusion Dependent Haemoglobinopathies[NCT01825512]	Phase 3	435 participants (Actual)	Interventional	2014-03-17	Completed
Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox[NCT03358498]		75 participants (Anticipated)	Observational	2017-12-01	Not yet recruiting
A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study[NCT02173951]	Phase 2/Phase 3	64 participants (Anticipated)	Interventional	2014-07-31	Not yet recruiting
The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome[NCT02477631]	Phase 2	19 participants (Actual)	Interventional	2016-02-29	Completed
A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload[NCT01511848]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2012-02-29	Not yet recruiting
A 24-Week, Open Label, Uncontrolled Study of the Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients With Transfusion-Dependent Anemia[NCT00529152]	Phase 3	100 participants (Actual)	Interventional	2007-08-31	Completed
Feasibility and Safety Pilot Therapeutic Study of the Iron Chelator Deferiprone in Amyotrophic Lateral Sclerosis[NCT02164253]	Phase 2	23 participants (Actual)	Interventional	2013-09-30	Completed
Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients[NCT00350662]	Phase 3	95 participants (Actual)	Interventional	2002-01-31	Completed
Platelet Changes in Cases of Chronic Iron Over Load[NCT04329286]		50 participants (Anticipated)	Observational	2020-04-01	Not yet recruiting
Platelet Changes in Cases of Iron Overload(IO)[NCT04329377]		50 participants (Anticipated)	Observational	2020-04-01	Not yet recruiting
Prospective Study on the Effect of Different Risk Factors on the Growth Parameters of Thalassemic Patients in Assiut University Children Hospital (AUCH)[NCT05303506]		50 participants (Anticipated)	Observational	2022-07-02	Not yet recruiting
Acute Effect of a Single Dose of Oral Iron on Pancreatic Beta Cell Function in Healthy Individuals: a Quasi-experimental Single Arm Before-and-after (Pre-post) Study[NCT05238987]		15 participants (Actual)	Interventional	2020-10-10	Completed
A Trial of Oral Nifedipine for the Treatment of Iron Overload[NCT00712738]	Phase 1	6 participants (Actual)	Interventional	2008-06-20	Completed
Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901]		150 participants (Actual)	Observational	2009-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Cardiac iron is measured by MRI in milliseconds (ms). A score of less than 20 ms is indicative of cardiac iron overload. (NCT02041299)
Timeframe: Change from baseline to Week 52

Change From Baseline in Liver Iron Concentration (LIC)

Intervention	milliseconds (Least Squares Mean)
Deferiprone	-0.022068
Deferoxamine	-0.021773

LIC was measured by MRI. A score >7 mg/g dw is indicative of iron overload. (NCT02041299)
Timeframe: Change from baseline to Week 52

Change From Baseline in Serum Ferritin

Intervention	mg of iron per gram of liver dry weight (Least Squares Mean)
Deferiprone	-4.13
Deferoxamine	-4.38

Serum ferritin provides a measure of iron level in the blood. Normal levels of serum ferritin are under 300 µg/L for females and 400 µg/L for males. (NCT02041299)
Timeframe: Change from baseline to Week 52

Change in Patient-reported Quality of Life, as Measured by the Short Form Health Survey (SF-36) or the Child Health Questionnaire (CHQ-PF50).

Intervention	micrograms per liter (Least Squares Mean)
Deferiprone	-385.83
Deferoxamine	-760.89

Adult patients completed the SF-36 questionnaire and minors completed the CHQ-PF50. These questionnaires yield a profile of functional health and well-being, based on 8 scales of physical and mental health measures: Physical Functioning, Role Limitations due to Physical Health, Bodily Pain, General Health Perceptions, Vitality, Social Functioning, Role Limitations due to Emotional Problems, and Mental Health (MH), and summary scores are produced for physical well-being and mental well-being. The summaries are scored from 0-100, with higher scores reflecting better outcomes. (NCT02041299)
Timeframe: Change from baseline to Week 52

Frequency of Adverse Events

Intervention	score on a scale (Mean)
	SF-36 Physical Summary	SF-36 Mental Summary	CHQ-PF50 Physical Summary	CHQ-PF50 Psychosocial Summary
Deferiprone	43.1	44.7	29.3	42.5
Deferoxamine	43.0	40.9	30.5	41.3

(NCT01835496)
Timeframe: From Day 1 (Dosing) to Day 7 plus/minus 3 days (Follow-up)

Frequency of Serious Adverse Events

AUC0-∞ for Serum Deferiprone and Deferiprone 3-O-glucuronide

Intervention	participants (Number)
Ferriprox	2

Intervention	participants (Number)
Ferriprox	0

AUC0-∞ (area under the curve, zero to infinity) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose. (NCT01835496)
Timeframe: 10-hour interval

Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide

Intervention	µg*hr/mL (Mean)
	AUC0-∞ for serum deferiprone	AUC0-∞ for serum deferiprone 3-O-glucuronide
Ferriprox	43.37	142.7

Cmax (maximum measured serum concentration) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose. (NCT01835496)
Timeframe: 10-hour interval

T1/2 for Serum Deferiprone and Deferiprone 3-O-glucuronide

Intervention	μg/mL (Mean)
	Cmax for serum deferiprone	Cmax for serum deferiprone 3-O-glucuronide
Ferriprox	17.56	32.95

T1/2 (apparent terminal elimination half-life) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose. (NCT01835496)
Timeframe: 10-hour interval

Tmax for Deferiprone and Deferiprone 3-O-glucuronide

Intervention	hr (Mean)
	T1/2 for serum deferiprone	T1/2 for serum deferiprone 3-O-glucuronide
Ferriprox	1.458	1.575

"Tmax (time to the maximum measured serum concentration) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose.~The results of the Tmax parameter are reported as the median and range (other parameters are reported as mean and standard deviation)." (NCT01835496)
Timeframe: 10-hour interval

Cardiac MRI T2*

Intervention	hr (Median)
	Tmax for serum seferiprone	Tmax for serum deferiprone 3-O-glucuronide
Ferriprox	1.000	2.750

Change in cardiac iron concentration (measured using cardiac MRI T2*), assessed as difference between value at 12 months minus value at baseline. MRI T2* is a non-invasive method based on gradient echo (GRE) sequences, where T2* represents the spin-spin relaxation times, measured in milliseconds. The faster the curve decreases (ie, the smaller T2*), the greater amount of iron is in the tissue. Treatment success was assessed as follows: if baseline cardiac T2* was less than 20 ms, an increase of 10% or more after 1 year of treatment was defined as treatment success; if baseline cardiac T2* was more than 20 ms, any increase or a decrease of less than 10% after 1 year of treatment was defined as treatment success. (NCT01825512)
Timeframe: at baseline and after 12 months

Ferritin Level

Intervention	milliseconds (ms) (Mean)
Deferiprone	0.488
Deferasirox	1.121

Change in serum ferritin level, assessed as difference between value at 12 months minus value at baseline. (NCT01825512)
Timeframe: at baseline and after 12 months

Liver MRI

Intervention	ng/mL (Mean)
Deferiprone	-397.583
Deferasirox	-398.184

Change in liver iron concentration (measured using liver MRI), assessed as difference between value at 12 months minus value at baseline. (NCT01825512)
Timeframe: at baseline and after 12 months

Percentage of Successfully Chelated Patients

Intervention	mg/g (Mean)
Deferiprone	-0.848
Deferasirox	-2.975

Percentage of successfully chelated patients is assessed by serum ferritin levels (in all patients) and cardiac MRI T2* (in patients above 10 years of age able to perform an MRI scan without sedation) (NCT01825512)
Timeframe: at baseline and after 12 months

Change in Serum Ferritin Concentration From Baseline.

Intervention	Participants (Count of Participants)
Deferiprone	69
Deferasirox	80

The change in serum ferritin concentration from baseline to week 24 was measured and analyzed for all participants in the study (NCT00529152)
Timeframe: Baseline and 24 weeks

Article	Year
Hydroxypyridinone-Based Iron Chelators with Broad-Ranging Biological Activities. Journal of medicinal chemistry, 2020, 12-10, Volume: 63, Issue:23 Topics: Animals; Humans; Iron Chelating Agents; Iron Overload; Pyridones	2020
Protective Effects of Curcumin against Iron-induced Toxicity. Current pharmaceutical biotechnology, 2022, Volume: 23, Issue:8 Topics: Curcumin; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones	2022
Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology. International journal of molecular sciences, 2022, Jun-16, Volume: 23, Issue:12 Topics: Adult; COVID-19 Drug Treatment; Deferiprone; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyr	2022
No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2023, Volume: 30, Issue:1 Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Ferritins; Hemoglobinopathies; Humans;	2023
Emerging Roles of the Iron Chelators in Inflammation. International journal of molecular sciences, 2022, Jul-20, Volume: 23, Issue:14 Topics: Animals; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Inflammation; Iron; Iron Chelating Agent	2022
Iron chelation therapy. European journal of haematology, 2023, Volume: 110, Issue:5 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating A	2023
Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects. International journal of molecular sciences, 2023, Mar-04, Volume: 24, Issue:5 Topics: Deferiprone; Drug Design; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones	2023
Clinical Challenges with Iron Chelation in Beta Thalassemia. Hematology/oncology clinics of North America, 2023, Volume: 37, Issue:2 Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyr	2023
Combination chelation therapy. Annals of the New York Academy of Sciences, 2023, Volume: 1529, Issue:1 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hum	2023
Rheumatological complications of beta-thalassaemia: an overview. Rheumatology (Oxford, England), 2018, 01-01, Volume: 57, Issue:1 Topics: Arthritis; beta-Thalassemia; Blood Transfusion; Connective Tissue Diseases; Deferiprone; Femur Head	2018
Deferiprone for the treatment of transfusional iron overload in thalassemia. Expert review of hematology, 2017, Volume: 10, Issue:6 Topics: Deferiprone; Erythrocyte Transfusion; Humans; Iron; Iron Overload; Myocardium; Neutropenia; Pyridone	2017
Deferasirox for managing iron overload in people with thalassaemia. The Cochrane database of systematic reviews, 2017, 08-15, Volume: 8 Topics: Administration, Oral; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as T	2017
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. Expert review of clinical pharmacology, 2018, Volume: 11, Issue:6 Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; H	2018
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. The Cochrane database of systematic reviews, 2018, 05-08, Volume: 5 Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Defer	2018
Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report. Acta medica Indonesiana, 2018, Volume: 50, Issue:2 Topics: Benzoates; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart; Humans;	2018
The Role of Deferiprone in Iron Chelation. The New England journal of medicine, 2018, 11-29, Volume: 379, Issue:22 Topics: Anemia, Sickle Cell; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Erythr	2018
Management of the thalassemias. Cold Spring Harbor perspectives in medicine, 2013, Jun-01, Volume: 3, Issue:6 Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron	2013
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. The Cochrane database of systematic reviews, 2013, Aug-21, Issue:8 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents;	2013
Oral deferiprone for iron chelation in people with thalassaemia. The Cochrane database of systematic reviews, 2013, Aug-21, Issue:8 Topics: Administration, Oral; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; I	2013
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes. Expert review of anticancer therapy, 2014, Volume: 14, Issue:7 Topics: Administration, Oral; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Def	2014
Antioxidant targeting by deferiprone in diseases related to oxidative damage. Frontiers in bioscience (Landmark edition), 2014, 06-01, Volume: 19, Issue:6 Topics: Acute Kidney Injury; Antioxidants; Cardiomyopathies; Deferiprone; Free Radicals; Friedreich Ataxia;	2014
A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia. Hemoglobin, 2014, Volume: 38, Issue:6 Topics: beta-Thalassemia; Blood Transfusion; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating Agent	2014
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia. Expert review of hematology, 2016, Volume: 9, Issue:2 Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Disease Mana	2016
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug design, development and therapy, 2016, Volume: 10 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents;	2016
Oral iron chelators. Annual review of medicine, 2009, Volume: 60 Topics: Administration, Oral; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agen	2009
Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes. Clinical lymphoma & myeloma, 2009, Volume: 9 Suppl 3 Topics: beta-Thalassemia; Deferiprone; Disease Progression; DNA Methylation; Erythrocyte Transfusion; Erythr	2009
Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert opinion on drug safety, 2010, Volume: 9, Issue:4 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Interactions; Drug Therap	2010
An update on disordered iron metabolism and iron overload. Hematology (Amsterdam, Netherlands), 2010, Volume: 15, Issue:5 Topics: Animals; Blood Transfusion; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron	2010
Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. Hematology/oncology clinics of North America, 2010, Volume: 24, Issue:6 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron	2010
Iron overload and allogeneic hematopoietic stem-cell transplantation. Expert review of hematology, 2011, Volume: 4, Issue:1 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematopoietic Stem Cell Transplantation; Humans;	2011
Iron chelation therapy for transfusional iron overload: a swift evolution. Hemoglobin, 2011, Volume: 35, Issue:5-6 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload	2011
Deferiprone (Ferriprox) for iron overload. The Medical letter on drugs and therapeutics, 2012, Feb-20, Volume: 54, Issue:1384 Topics: Animals; Clinical Trials as Topic; Deferiprone; Humans; Iron Overload; Pyridones; Thalassemia; Trans	2012
Iron chelation therapy in the management of transfusion-related cardiac iron overload. Transfusion, 2012, Volume: 52, Issue:10 Topics: Benzoates; Cardiomyopathy, Dilated; Chelation Therapy; Cross-Sectional Studies; Deferasirox; Deferip	2012
Iron mobilization using chelation and phlebotomy. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2012, Volume: 26, Issue:2-3 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overloa	2012
Management of transfusion-related iron overload in patients with myelodysplastic syndromes. Clinical journal of oncology nursing, 2012, Volume: 16 Suppl Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating A	2012
[Iron chelating therapy in adults: How and when ?]. La Revue de medecine interne, 2013, Volume: 34, Issue:1 Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Ir	2013
Orally active iron chelators. Blood reviews, 2002, Volume: 16, Issue:2 Topics: Administration, Oral; Anemia; Blood Transfusion; Deferiprone; Humans; Iron Chelating Agents; Iron Ov	2002
Long term deferiprone chelation therapy. Advances in experimental medicine and biology, 2002, Volume: 509 Topics: Animals; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iro	2002
Role of deferiprone in chelation therapy for transfusional iron overload. Blood, 2003, Jul-01, Volume: 102, Issue:1 Topics: Chelation Therapy; Deferiprone; Humans; Iron Overload; Pyridones; Transfusion Reaction; Treatment Ou	2003
Iron chelation in chemotherapy. Advances in applied microbiology, 2003, Volume: 52 Topics: Animals; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Lactoferrin; Pyrid	2003
Pharmacotherapy of iron overload in thalassaemic patients. Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:10 Topics: Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; I	2003
Purging iron from the heart. British journal of haematology, 2004, Volume: 125, Issue:5 Topics: Cardiomyopathies; Cardiotonic Agents; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron	2004
LPI-labile plasma iron in iron overload. Best practice & research. Clinical haematology, 2005, Volume: 18, Issue:2 Topics: beta-Thalassemia; Deferiprone; Humans; Iron; Iron Chelating Agents; Iron Overload; Oxidation-Reducti	2005
Deferiprone therapy for transfusional iron overload. Best practice & research. Clinical haematology, 2005, Volume: 18, Issue:2 Topics: Chelation Therapy; Clinical Trials as Topic; Deferiprone; Dose-Response Relationship, Drug; Heart Di	2005
Monitoring and treatment of iron overload: state of the art and new approaches. Seminars in hematology, 2005, Volume: 42, Issue:2 Suppl 1 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Hemosiderin; Humans; Iron; Iron Chelat	2005
Treating iron overload: the state of the art. Seminars in hematology, 2005, Volume: 42, Issue:2 Suppl 1 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overloa	2005
Beta-thalassemia. The New England journal of medicine, 2005, Sep-15, Volume: 353, Issue:11 Topics: Antioxidants; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Deferiprone; Hematopoietic Ste	2005
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. The Cochrane database of systematic reviews, 2005, Oct-19, Issue:4 Topics: Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridone	2005
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Current medicinal chemistry, 2005, Volume: 12, Issue:23 Topics: Benzoates; Carboxylic Acids; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemo	2005
Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators. Current medicinal chemistry, 2005, Volume: 12, Issue:23 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overloa	2005
Objectives and mechanism of iron chelation therapy. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic;	2005
Combined therapy with deferoxamine and deferiprone. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Agranulocytosis; Biological Transport; Cardiomyopathies; Chelation Therapy; Clinical Trials as Topic	2005
Deferiprone: New insight. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Agranulocytosis; Cardiomyopathies; Clinical Trials as Topic; Deferiprone; Deferoxamine; Follow-Up St	2005
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Algorithms; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine;	2005
T2* magnetic resonance and myocardial iron in thalassemia. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Adult; Calibration; Cardiomyopathies; Chelation Therapy; Child; Cohort Studies; Combined Modality Th	2005
Myelodysplastic syndromes: iron overload consequences and current chelating therapies. Journal of the National Comprehensive Cancer Network : JNCCN, 2006, Volume: 4, Issue:1 Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythroc	2006
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood, 2006, May-01, Volume: 107, Issue:9 Topics: Administration, Oral; Benzoates; beta-Thalassemia; Clinical Trials as Topic; Costs and Cost Analysis	2006
Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Anemia; Chelation Therapy; Chronic Disease; Combined Modality Therapy; Deferiprone; Humans; Iron; Ir	2006
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone;	2006
Chelation therapy for iron overload. Current gastroenterology reports, 2007, Volume: 9, Issue:1 Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferipron	2007
Oral deferiprone for iron chelation in people with thalassaemia. The Cochrane database of systematic reviews, 2007, Jul-18, Issue:3 Topics: Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridone	2007
Light and shadows in the iron chelation treatment of haematological diseases. British journal of haematology, 2007, Volume: 138, Issue:4 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans;	2007
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion, 2007, Volume: 47, Issue:10 Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cost of Illness; Deferiprone; Deferoxamine; Humans	2007
Coordination chemistry and biology of chelators for the treatment of iron overload disorders. Dalton transactions (Cambridge, England : 2003), 2007, Aug-14, Issue:30 Topics: Benzoates; Chemistry, Pharmaceutical; Crystallography, X-Ray; Deferasirox; Deferiprone; Deferoxamine	2007
Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Leukemia research, 2007, Volume: 31 Suppl 3 Topics: Benzoates; Deferasirox; Deferiprone; Drug-Related Side Effects and Adverse Reactions; Humans; Iron C	2007
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin, 2008, Volume: 32, Issue:1-2 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Approval; Drug Therapy, C	2008
Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. Hemoglobin, 2008, Volume: 32, Issue:1-2 Topics: Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelat	2008
Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy. Pharmacotherapy, 2008, Volume: 28, Issue:3 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Diet; Drug Therapy, Combination; Humans; Iron Che	2008
Oral iron chelators. Pediatric clinics of North America, 2008, Volume: 55, Issue:2 Topics: Administration, Oral; Benzoates; Chelating Agents; Child; Deferasirox; Deferiprone; Deferoxamine; Er	2008
Oral iron chelation with deferiprone. Pediatric clinics of North America, 1997, Volume: 44, Issue:1 Topics: Acute Disease; Administration, Oral; Anemia; Chelation Therapy; Child; Deferiprone; Humans; Iron Ove	1997
Orally active iron chelators in the treatment of iron overload. Current opinion in hematology, 1996, Volume: 3, Issue:2 Topics: Administration, Oral; Agranulocytosis; Chelation Therapy; Clinical Trials as Topic; Deferiprone; Hum	1996
A risk-benefit assessment of iron-chelation therapy. Drug safety, 1997, Volume: 17, Issue:6 Topics: Administration, Oral; Clinical Trials as Topic; Deferiprone; Deferoxamine; Guidelines as Topic; Huma	1997
Iron chelators for thalassaemia. British journal of haematology, 1998, Volume: 101, Issue:3 Topics: Administration, Oral; Aza Compounds; Chelating Agents; Deferiprone; Deferoxamine; Edetic Acid; Human	1998
Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs. The Journal of laboratory and clinical medicine, 1998, Volume: 132, Issue:4 Topics: Administration, Oral; Animals; Deferiprone; Ferritins; Iron; Iron Chelating Agents; Iron Overload; I	1998
[Iron chelation in 1998]. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 1998, Volume: 5, Issue:5 Topics: Administration, Oral; Deferiprone; Deferoxamine; Ferritins; Humans; Injections, Intramuscular; Injec	1998
Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). European journal of clinical pharmacology, 1999, Volume: 55, Issue:1 Topics: Administration, Oral; Deferiprone; Drug Evaluation; Ferritins; Humans; Iron Chelating Agents; Iron O	1999
Oral iron chelation therapy for thalassaemia: an uncertain scene. British journal of haematology, 2000, Volume: 111, Issue:1 Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron	2000
Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfusion science, 2000, Volume: 23, Issue:3 Topics: Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reac	2000
[Iron overload and myelodysplastic syndromes]. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2001, Volume: 8, Issue:5 Topics: Administration, Oral; Aged; Biopsy; Chelation Therapy; Deferiprone; Deferoxamine; Erythrocyte Transf	2001

Article	Year
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood advances, 2022, 02-22, Volume: 6, Issue:4 Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Deferiprone; Deferoxamine; Female; Humans; Iron	2022
The safety and acceptability of twice-daily deferiprone for transfusional iron overload: A multicentre, open-label, phase 2 study. British journal of haematology, 2022, Volume: 197, Issue:1 Topics: Deferiprone; Humans; Iron Chelating Agents; Iron Overload	2022
The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease. Annals of hematology, 2022, Volume: 101, Issue:3 Topics: Adult; Anemia, Sickle Cell; Blood Transfusion; Chelation Therapy; Deferiprone; Female; Humans; Iron	2022
Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254. Blood advances, 2023, 06-27, Volume: 7, Issue:12 Topics: Anemia; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload	2023
Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. Pediatric blood & cancer, 2024, Volume: 71, Issue:1 Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Humans; Iron; Iron C	2024
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. The Lancet. Haematology, 2020, Volume: 7, Issue:6 Topics: Administration, Oral; Adolescent; Agranulocytosis; Albania; Anemia, Sickle Cell; beta-Thalassemia; C	2020
Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial. American journal of hematology, 2018, Volume: 93, Issue:2 Topics: Blood Transfusion; Chelation Therapy; Deferiprone; Female; Ferritins; Humans; Infant; Iron Chelating	2018
Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden. Journal of pediatric hematology/oncology, 2019, Volume: 41, Issue:1 Topics: Adult; Blood Transfusion; Deferasirox; Deferiprone; Drug Therapy, Combination; Female; Follow-Up Stu	2019
Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study. Expert review of hematology, 2019, Volume: 12, Issue:4 Topics: Administration, Oral; Adult; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Deferasirox; De	2019
Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. American journal of hematology, 2013, Volume: 88, Issue:4 Topics: Acute Disease; Administration, Oral; Adolescent; beta-Thalassemia; Child; Child, Preschool; Deferipr	2013
Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial. Blood cells, molecules & diseases, 2014, Volume: 53, Issue:4 Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Transfusion; Child; Deferiprone; Deferoxamine; Female;	2014
Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European journal of haematology, 2015, Volume: 95, Issue:5 Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxa	2015
Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial. American journal of hematology, 2015, Volume: 90, Issue:7 Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine;	2015
Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major. Infectious disorders drug targets, 2015, Volume: 15, Issue:3 Topics: Administration, Oral; Antioxidants; beta-Thalassemia; Blood Chemical Analysis; Blood Transfusion; Ch	2015
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. European journal of haematology, 2009, Volume: 82, Issue:6 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferiprone; Deferoxa	2009
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. British journal of haematology, 2010, Volume: 148, Issue:3 Topics: Adolescent; Adult; beta-Thalassemia; Blood Glucose; Cardiomyopathies; Child; Deferiprone; Deferoxami	2010
Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study. European journal of haematology, 2010, Volume: 85, Issue:1 Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Administrati	2010
Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. European journal of haematology, 2010, Volume: 85, Issue:5 Topics: Adult; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron C	2010
The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. Journal of pediatric hematology/oncology, 2010, Volume: 32, Issue:8 Topics: Administration, Oral; Agranulocytosis; Anemia, Sickle Cell; beta-Thalassemia; Chemistry, Pharmaceuti	2010
Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. Hematology (Amsterdam, Netherlands), 2011, Volume: 16, Issue:2 Topics: Adolescent; Adult; beta-Thalassemia; Cardiovascular Abnormalities; Deferiprone; Echocardiography, Do	2011
Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. Hemoglobin, 2011, Volume: 35, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Deferiprone; Drug Therapy, Combination; Drug-Relate	2011
Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response. Haematologica, 2012, Volume: 97, Issue:6 Topics: Adolescent; beta-Thalassemia; Blood Proteins; Blood Transfusion; Chelation Therapy; Child; Deferipro	2012
Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. British journal of haematology, 2003, Volume: 121, Issue:1 Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Chelating Agents; Child; Deferiprone; Defero	2003
Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan. European journal of haematology, 2003, Volume: 70, Issue:6 Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; Deferoxamine; Female; Fe	2003
Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica, 2003, Volume: 88, Issue:12 Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Combined Modality Therapy; Deferiprone; Defe	2003
Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients. Haematologica, 2004, Volume: 89, Issue:4 Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Com	2004
Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood, 2004, Sep-01, Volume: 104, Issue:5 Topics: beta-Thalassemia; Biomarkers; Deferiprone; Erythrocyte Membrane; Follow-Up Studies; Hemoglobin E; Hu	2004
Deferiprone as an oral iron chelator in sickle cell disease. Annals of hematology, 2005, Volume: 84, Issue:7 Topics: Administration, Oral; Adult; Aged; Anemia, Sickle Cell; beta-Thalassemia; Deferiprone; Drug Evaluati	2005
Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Annals of hematology, 2006, Volume: 85, Issue:5 Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Deferiprone; Deferoxamine; Erythrocyte	2006
Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2. European journal of haematology, 2006, Volume: 76, Issue:3* Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Humans; Iron Overload; Magnetic Resonanc	2006
Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy. Pediatric endocrinology reviews : PER, 2004, Volume: 2 Suppl 2 Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Thera	2004
Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease. British journal of haematology, 2006, Volume: 133, Issue:2 Topics: Administration, Oral; Adult; Aged; alpha-Thalassemia; Deferiprone; Diastole; Echocardiography, Doppl	2006
Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Combined Modali	2006
A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Adolescent; Adult; Arthralgia; beta-Thalassemia; Biopsy, Needle; Chelation Therapy; Child; Combined	2006
A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica, 2006, Volume: 91, Issue:9 Topics: Adolescent; Adult; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Overlo	2006
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation, 2007, Apr-10, Volume: 115, Issue:14 Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine;	2007
Pharmacokinetic disposition of the oral iron chelator deferiprone in the white leghorn chicken. Journal of avian medicine and surgery, 2007, Volume: 21, Issue:2 Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Chickens; Chromatography,	2007
Pharmacokinetic disposition of the oral iron chelator deferiprone in the domestic pigeon (Columba livia). Journal of avian medicine and surgery, 2007, Volume: 21, Issue:2 Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Chromatography, High Press	2007
Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Annals of hematology, 2008, Volume: 87, Issue:7 Topics: Adolescent; Adult; Chelation Therapy; Child; Child, Preschool; Deferiprone; Deferoxamine; Drug Admin	2008
Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood, 1998, Jan-01, Volume: 91, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Chelating	1998
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. The New England journal of medicine, 1998, Aug-13, Volume: 339, Issue:7 Topics: Adolescent; Adult; beta-Thalassemia; Biopsy; Child; Deferiprone; Deferoxamine; Disease Progression;	1998
Combined therapy with deferiprone and desferrioxamine. British journal of haematology, 1998, Volume: 103, Issue:2 Topics: Adolescent; Adult; Aged; beta-Thalassemia; Deferiprone; Deferoxamine; Dose-Response Relationship, Dr	1998
A trial of deferiprone in transfusion-dependent iron overloaded children. The Ceylon medical journal, 2000, Volume: 45, Issue:2 Topics: Adolescent; beta-Thalassemia; Child; Child, Preschool; Deferiprone; Ferritins; Humans; Iron Chelatin	2000
Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. European journal of haematology, 2001, Volume: 67, Issue:1 Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; De	2001

Article	Year
Basic 3-hydroxypyridin-4-ones: potential antimalarial agents. European journal of medicinal chemistry, 2008, Volume: 43, Issue:5 Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Iron; Iron Chelating Agents; Iron Overload; Ma	2008
Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Adamantane; Administration, Oral; Animals; Binding Sites; Carboxylic Acids; Cell Proliferation; Cell	2010
CN128: A New Orally Active Hydroxypyridinone Iron Chelator. Journal of medicinal chemistry, 2020, 04-23, Volume: 63, Issue:8 Topics: Administration, Oral; Animals; Dose-Response Relationship, Drug; Guinea Pigs; Humans; Iron Chelating	2020
Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy. Journal of cachexia, sarcopenia and muscle, 2022, Volume: 13, Issue:3 Topics: Animals; Deferiprone; Dystrophin; Ferritins; Fibrosis; Heme; Iron; Iron Chelating Agents; Iron Overl	2022
Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine. Scientific reports, 2022, 06-13, Volume: 12, Issue:1 Topics: Animals; Catecholamines; Deferasirox; Deferiprone; Deferoxamine; Dopamine; Iron; Iron Chelating Agen	2022
Agranulocytosis in patients with Diamond-Blackfan anaemia (DBA) treated with deferiprone for post-transfusion iron overload: A retrospective study of the French DBA cohort. British journal of haematology, 2022, Volume: 199, Issue:2 Topics: Agranulocytosis; Anemia, Diamond-Blackfan; Deferiprone; Humans; Iron Overload; Retrospective Studies	2022
Diamond-Blackfan anaemia with iron overload: A serious issue. British journal of haematology, 2022, Volume: 199, Issue:2 Topics: Agranulocytosis; Anemia, Diamond-Blackfan; Chelating Agents; Deferiprone; Humans; Iron; Iron Overloa	2022
Deferiprone has less benefits on gut microbiota and metabolites in high iron-diet induced iron overload thalassemic mice than in iron overload wild-type mice: A preclinical study. Life sciences, 2022, Oct-15, Volume: 307 Topics: Animals; Cytokines; Deferiprone; Diet; Dysbiosis; Gastrointestinal Microbiome; Inflammation; Iron; I	2022
New Deferric Amine Compounds Efficiently Chelate Excess Iron to Treat Iron Overload Disorders and to Prevent Ferroptosis. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022, Volume: 9, Issue:29 Topics: Amines; Animals; Deferiprone; Deferoxamine; Dextrans; Ferroptosis; Hemochromatosis; Humans; Iron; Ir	2022
Iron chelation alleviates multiple pathophysiological pathways in a rat model of cardiac pressure overload. Free radical biology & medicine, 2023, 05-01, Volume: 200 Topics: Animals; Deferiprone; Heart Failure, Systolic; Inflammation; Iron; Iron Chelating Agents; Iron Overl	2023
Nephrolithiasis in two patients on iron chelation therapy: A case report. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2023, Volume: 62, Issue:3 Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Human	2023
Combined iron chelator with N-acetylcysteine exerts the greatest effect on improving cardiac calcium homeostasis in iron-overloaded thalassemic mice. Toxicology, 2019, 11-01, Volume: 427 Topics: Acetylcysteine; Animals; Calcium; Deferiprone; Heart; Homeostasis; Iron Chelating Agents; Iron Overl	2019
Deferiprone and efonidipine mitigated iron-overload induced neurotoxicity in wild-type and thalassemic mice. Life sciences, 2019, Dec-15, Volume: 239 Topics: Animals; Calcium Channel Blockers; Calcium Channels, T-Type; Deferiprone; Dihydropyridines; Disease	2019
Prospective CMR Survey in Children With Thalassemia Major: Insights From a National Network. JACC. Cardiovascular imaging, 2020, Volume: 13, Issue:5 Topics: Adolescent; Age Factors; beta-Thalassemia; Cardiomyopathies; Child; Deferiprone; Deferoxamine; Femal	2020
Differential effects of Fe2+ and Fe3+ on osteoblasts and the effects of 1,25(OH)2D3, deferiprone and extracellular calcium on osteoblast viability under iron-overloaded conditions. PloS one, 2020, Volume: 15, Issue:5 Topics: Animals; Biomarkers; Calcification, Physiologic; Calcitriol; Calcium; Cell Cycle Checkpoints; Cell D	2020
Cardiac T2* MR in patients with thalassemia major: a 10-year long-term follow-up. Annals of hematology, 2020, Volume: 99, Issue:9 Topics: Adolescent; beta-Thalassemia; Chelation Therapy; Cohort Studies; Deferasirox; Deferiprone; Female; F	2020
Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study. Indian journal of pediatrics, 2021, Volume: 88, Issue:4 Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Ov	2021
Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities. Folia medica, 2020, Jun-30, Volume: 62, Issue:2 Topics: Adult; beta-Thalassemia; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Female; Ferritin	2020
Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria. Blood, 2020, 11-19, Volume: 136, Issue:21 Topics: 5-Aminolevulinate Synthetase; Adult; Anemia, Hemolytic; Animals; Cell Line; Cell Line, Tumor; CRISPR	2020
Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. Annals of hematology, 2020, Volume: 99, Issue:10 Topics: Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Deferiprone; Deferoxamine; Drug Evaluati	2020
Silencing of lipocalin-2 improves cardiomyocyte viability under iron overload conditions via decreasing mitochondrial dysfunction and apoptosis. Journal of cellular physiology, 2021, Volume: 236, Issue:7 Topics: Animals; Apoptosis; Calcium Channels, L-Type; Calcium Channels, T-Type; Cell Line; Cell Survival; De	2021
Dual Oral Iron Chelation in Thalassemia: Need for Robust Evidence. Indian journal of pediatrics, 2021, Volume: 88, Issue:4 Topics: Child; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies;	2021
Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran. Hemoglobin, 2021, Volume: 45, Issue:2 Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine;	2021
SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia. British journal of haematology, 2021, Volume: 194, Issue:1 Topics: Acetylgalactosamine; Animals; beta-Thalassemia; Deferiprone; Disease Models, Animal; Drug Therapy, C	2021
Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone. Molecules (Basel, Switzerland), 2021, Aug-20, Volume: 26, Issue:16 Topics: Antioxidants; Ascorbic Acid; Coordination Complexes; Deferasirox; Deferiprone; Humans; Iron; Iron Ch	2021
Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination. Drug research, 2017, Volume: 67, Issue:7 Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; He	2017
Prevalence of diabetes mellitus in Chinese children with thalassaemia major. Tropical medicine & international health : TM & IH, 2017, Volume: 22, Issue:6 Topics: Alanine Transaminase; beta-Thalassemia; Blood Glucose; Child; China; Deferiprone; Diabetes Mellitus;	2017
Chelation protocols for the elimination and prevention of iron overload in thalassaemia. Frontiers in bioscience (Landmark edition), 2018, 01-01, Volume: 23, Issue:6 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hum	2018
Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study. Haematologica, 2018, Volume: 103, Issue:1 Topics: Age Factors; beta-Thalassemia; Child; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Med	2018
Deferiprone inhibits iron overload-induced tissue factor bearing endothelial microparticle generation by inhibition oxidative stress induced mitochondrial injury, and apoptosis. Toxicology and applied pharmacology, 2018, 01-01, Volume: 338 Topics: Adenosine Triphosphate; Apoptosis; Cell-Derived Microparticles; Cells, Cultured; Deferiprone; Endoth	2018
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit? Leukemia research, 2018, Volume: 64 Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine	2018
Activation of the molecular and functional effects of Nrf2 against chronic iron oxide nanorod overload-induced cardiotoxicity. Human & experimental toxicology, 2018, Volume: 37, Issue:8 Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Cardiotoxicity; Deferiprone; Deferoxamine; Deoxyguanosine; Glu	2018
Glucose Homeostasis and Effect of Chelation on β Cell Function in Children With β-Thalassemia Major. Journal of pediatric hematology/oncology, 2018, Volume: 40, Issue:1 Topics: Adolescent; beta-Thalassemia; Blood Glucose; Chelation Therapy; Child; Child, Preschool; Deferiprone	2018
Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia major. Annals of hematology, 2018, Volume: 97, Issue:4 Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Blood Transfusion; Chelation Therapy; Combined Moda	2018
Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience. La Radiologia medica, 2018, Volume: 123, Issue:8 Topics: Adolescent; Adult; Benzoates; Blood Component Transfusion; Chelation Therapy; Child; Deferasirox; De	2018
The kinetics of dimethylhydroxypyridinone interactions with iron(iii) and the catalysis of iron(iii) ligand exchange reactions: implications for bacterial iron transport and combination chelation therapies. Dalton transactions (Cambridge, England : 2003), 2018, May-22, Volume: 47, Issue:20 Topics: Bacteria; Catalysis; Chelation Therapy; Deferiprone; Deferoxamine; Edetic Acid; Ferric Compounds; Hu	2018
Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients. American journal of hematology, 2018, Volume: 93, Issue:10 Topics: Adolescent; Adult; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Drug Administrati	2018
Hepatic and Cardiac Iron Overload - Revising the Role of Deferiprone. Indian pediatrics, 2018, 07-15, Volume: 55, Issue:7 Topics: beta-Thalassemia; Deferiprone; Heart; Humans; Iron Chelating Agents; Iron Overload; Pyridones	2018
Hepatic and Cardiac Iron-load in Children on Long-term Chelation with Deferiprone for Thalassemia Major. Indian pediatrics, 2018, 07-15, Volume: 55, Issue:7 Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Child; Cross-Sectional Studies; Deferiprone; Drug A	2018
Life-Threatening Drug-Induced Liver Injury in a Patient with β-Thalassemia Major and Severe Iron Overload on Polypharmacy. Hemoglobin, 2018, Volume: 42, Issue:3 Topics: Adrenergic beta-Antagonists; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver In	2018
MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine. British journal of haematology, 2018, Volume: 183, Issue:5 Topics: Adult; beta-Thalassemia; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Substitution	2018
Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one? The Indian journal of medical research, 2018, Volume: 148, Issue:4 Topics: Animals; beta-Thalassemia; Chelating Agents; Deferiprone; Deferoxamine; Humans; Hydroxyurea; Iron Ov	2018
Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. PloS one, 2019, Volume: 14, Issue:2 Topics: Administration, Oral; Anemia, Diamond-Blackfan; beta-Thalassemia; Blood Transfusion; Deferasirox; De	2019
Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload. European journal of haematology, 2019, Volume: 103, Issue:2 Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Biomarkers; Deferiprone; Humans; Iron; Iro	2019
MRI imaging and histopathological study of brain iron overload of β-thalassemic mice. Magnetic resonance imaging, 2019, Volume: 61 Topics: Animals; beta-Thalassemia; Brain; Chelating Agents; Computer Graphics; Deferiprone; Disease Models,	2019
Renal iron accelerates the progression of diabetic nephropathy in the HFE gene knockout mouse model of iron overload. American journal of physiology. Renal physiology, 2019, 08-01, Volume: 317, Issue:2 Topics: Animals; Deferiprone; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression;	2019
Deferiprone-induced seizures in a patient with β-thalassemia major. Blood cells, molecules & diseases, 2013, Volume: 51, Issue:2 Topics: Adult; beta-Thalassemia; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones;	2013
Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project. British journal of haematology, 2013, Volume: 161, Issue:6 Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine;	2013
Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major. Blood cells, molecules & diseases, 2013, Volume: 51, Issue:2 Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Heart Diseases; Humans; Iron Chelating A	2013
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Expert opinion on drug safety, 2013, Volume: 12, Issue:5 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Mar	2013
Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective. PharmacoEconomics, 2013, Volume: 31, Issue:9 Topics: beta-Thalassemia; Cost-Benefit Analysis; Deferiprone; Drug Costs; Health Care Costs; Humans; Iron Ch	2013
A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. Leukemia research, 2013, Volume: 37, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Female; Ferr	2013
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Defer	2013
Three most common nonsynonymous UGT1A62 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients. Gene, 2013, Dec-01, Volume: 531, Issue:2* Topics: Adolescent; Alanine; Amino Acid Substitution; Arginine; beta-Thalassemia; Child; Child, Preschool; D	2013
Iron chelators in myelodysplastic syndrome: to lower ferritin levels or to improve survival? Leukemia research, 2013, Volume: 37, Issue:12 Topics: Benzoates; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Mye	2013
Korean guideline for iron chelation therapy in transfusion-induced iron overload. Journal of Korean medical science, 2013, Volume: 28, Issue:11 Topics: Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Age	2013
Assessment of labile plasma iron in patients who undergo hematopoietic stem cell transplantation. Acta haematologica, 2014, Volume: 131, Issue:4 Topics: Adult; Aged; Antioxidants; Ascorbic Acid; Cohort Studies; Deferiprone; Female; Fluorescent Dyes; Fol	2014
Deferiprone, iron overload in a renal transplant patient. QJM : monthly journal of the Association of Physicians, 2014, Volume: 107, Issue:6 Topics: Aged; Deferiprone; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Kidney Transplantation;	2014
Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis. Pediatric blood & cancer, 2014, Volume: 61, Issue:5 Topics: Adolescent; Adult; Agranulocytosis; Blood Transfusion; Child; Child, Preschool; Deferiprone; Female;	2014
The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice. Investigative ophthalmology & visual science, 2014, Jun-26, Volume: 55, Issue:7 Topics: Administration, Oral; Animals; Deferiprone; Disease Models, Animal; Electroretinography; Ferritins;	2014
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents. Hemoglobin, 2014, Volume: 38, Issue:5 Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone;	2014
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study. Pediatric blood & cancer, 2015, Volume: 62, Issue:9 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver I	2015
Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia. British journal of haematology, 2015, Volume: 171, Issue:3 Topics: Adult; Ceruloplasmin; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Diseases; Humans;	2015
Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience. Paediatrics and international child health, 2016, Volume: 36, Issue:3 Topics: Anemia, Hemolytic; Child; Child, Preschool; Deferiprone; Female; Ferritins; Humans; Iron Chelating A	2016
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload. Infectious disorders drug targets, 2015, Volume: 15, Issue:2 Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; D	2015
Effects of Iron Chelators on Pulmonary Iron Overload and Oxidative Stress in β-Thalassemic Mice. Pharmacology, 2015, Volume: 96, Issue:3-4 Topics: Animals; Antidotes; beta-Globins; beta-Thalassemia; Deferiprone; Deferoxamine; Dextrans; Female; Fib	2015
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. Experimental physiology, 2016, Volume: 101, Issue:4 Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Ca	2016
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. Annals of hematology, 2016, Volume: 95, Issue:5 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabe	2016
Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia. Indian pediatrics, 2016, Volume: 53, Issue:3 Topics: Adolescent; Benzoates; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Therapy, Combination;	2016
Deferiprone-induced agranulocytosis: 20 years of clinical observations. American journal of hematology, 2016, Volume: 91, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Agranulocytosis; Child; Child, Preschool; Clinical Trial	2016
Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats. PloS one, 2016, Volume: 11, Issue:7 Topics: Acetylcysteine; Animals; Benzoates; Cardiomyopathies; Cardiotonic Agents; Deferasirox; Deferiprone;	2016
Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:1 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Creatinine; Cross-Sectional Studies; Deferasirox; De	2017
Effect of Systemic Iron Overload and a Chelation Therapy in a Mouse Model of the Neurodegenerative Disease Hereditary Ferritinopathy. PloS one, 2016, Volume: 11, Issue:8 Topics: Animals; Apoferritins; Cell Survival; Cells, Cultured; Chelation Therapy; Deferiprone; Disease Model	2016
Tetrahydrocurcumin in combination with deferiprone attenuates hypertension, vascular dysfunction, baroreflex dysfunction, and oxidative stress in iron-overloaded mice. Vascular pharmacology, 2016, Volume: 87 Topics: Administration, Oral; Animals; Baroreflex; Curcumin; Deferiprone; Disease Models, Animal; Drug Thera	2016
Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone. The Canadian journal of cardiology, 2016, Volume: 32, Issue:12 Topics: Cardiomyopathies; Deferiprone; Deferoxamine; Ferritins; Heart Failure; Hemochromatosis; Hemochromato	2016
Effects of iron overload, an iron chelator and a T-Type calcium channel blocker on cardiac mitochondrial biogenesis and mitochondrial dynamics in thalassemic mice. European journal of pharmacology, 2017, Mar-15, Volume: 799 Topics: Aminophylline; Animals; Apoptosis; Atropine; Blood Pressure; Calcium Channel Blockers; Calcium Chann	2017
Long-term efficacy of oral deferiprone in management of iron overload in beta thalassemia major. Hematology (Amsterdam, Netherlands), 2008, Volume: 13, Issue:2 Topics: Adolescent; beta-Thalassemia; Child; Deferiprone; Disease Management; Drug Evaluation; Female; Ferri	2008
Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Advances in therapy, 2008, Volume: 25, Issue:8 Topics: Adolescent; Adult; Chelation Therapy; Child; Costs and Cost Analysis; Deferiprone; Deferoxamine; Fem	2008
Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Advances in therapy, 2008, Volume: 25, Issue:8 Topics: Adolescent; Adult; Chelation Therapy; Child; Costs and Cost Analysis; Deferiprone; Deferoxamine; Fem	2008
Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Advances in therapy, 2008, Volume: 25, Issue:8 Topics: Adolescent; Adult; Chelation Therapy; Child; Costs and Cost Analysis; Deferiprone; Deferoxamine; Fem	2008
Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Advances in therapy, 2008, Volume: 25, Issue:8 Topics: Adolescent; Adult; Chelation Therapy; Child; Costs and Cost Analysis; Deferiprone; Deferoxamine; Fem	2008
Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2008, Sep-25, Volume: 10 Topics: Adolescent; Adult; Anemia; beta-Thalassemia; Bone Marrow Transplantation; Cardiomyopathies; Cause of	2008
Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients. Expert opinion on drug safety, 2008, Volume: 7, Issue:6 Topics: Benzoates; Deferasirox; Deferiprone; Drug Therapy, Combination; Heart; Humans; Iron Chelating Agents	2008
Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin, 2008, Volume: 32, Issue:6 Topics: Acute Kidney Injury; Benzoates; Chelation Therapy; Cost-Benefit Analysis; Deferasirox; Deferiprone;	2008
High doses of deferiprone may be associated with cerebellar syndrome. BMJ (Clinical research ed.), 2009, Jan-22, Volume: 338 Topics: beta-Thalassemia; Cerebellar Diseases; Child; Deferiprone; Female; Humans; Iron Chelating Agents; Ir	2009
Effect of iron-chelator deferiprone on the in vitro growth of staphylococci. Journal of Korean medical science, 2009, Volume: 24, Issue:2 Topics: Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Microbial Sensitivity	2009
Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus. Transfusion, 2009, Volume: 49, Issue:8 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Overload; Pyridones; Siderophores; T	2009
Long-term response to deferiprone therapy in Asian Indians. Annals of hematology, 2010, Volume: 89, Issue:2 Topics: Adolescent; Adult; Agranulocytosis; Asian People; Chelation Therapy; Child; Child, Preschool; Deferi	2010
Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2009, Volume: 108, Issue:4 Topics: Adolescent; Agranulocytosis; Alveolar Process; beta-Thalassemia; Blood Transfusion; Deferiprone; Dia	2009
Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Chelation Therapy; Chronic Disease; Cyprus; Deferiprone; Deferoxamine; Female; Ferritins; Genetic Te	2009
Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxa Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Adolescent; Adult; Chelation Therapy; Child; Deferiprone; Deferoxamine; Diagnosis, Differential; Dru	2009
A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Blood Transfusion; Chelation Therapy; Clinical Protocols; Deferiprone; Deferoxamine; Drug Therapy, C	2009
A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2. Hemoglobin, 2009, Volume: 33, Issue:5* Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Clinical Protocols;	2009
Treatment with deferiprone for iron overload alleviates bone marrow failure in a Fanconi anemia patient. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Bone Marrow; Child; Deferiprone; Fanconi Anemia; Ferritins; Hematopoietic Stem Cell Transplantation;	2009
Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Aeromonas hydrophila; Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Gram-Neg	2009
Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Animals; Antioxidants; Benzoates; Chelation Therapy; Copper; Deferasirox; Deferiprone; Deferoxamine;	2009
Early cardiac iron overload in children with transfusion-dependent anemias. Haematologica, 2009, Volume: 94, Issue:12 Topics: Adolescent; Anemia; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Deferiprone; Defe	2009
Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells. Acta haematologica, 2010, Volume: 123, Issue:1 Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Erythrocytes; Erythroid Cells;	2010
Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction. Blood reviews, 2009, Volume: 23 Suppl 1 Topics: Anemia; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Ove	2009
Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice. Medicinal chemistry (Shariqah (United Arab Emirates)), 2010, Volume: 6, Issue:2 Topics: Administration, Oral; Animals; beta-Thalassemia; Collagen; Deferiprone; Dietary Supplements; Ferrous	2010
Iron chelation therapy in myelodysplastic syndromes. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2010, Volume: 67, Issue:7 Suppl 2 Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Education, Continuing; Hum	2010
New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores. British journal of haematology, 2010, Volume: 150, Issue:4 Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Fe	2010
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients. American journal of hematology, 2010, Volume: 85, Issue:6 Topics: Administration, Oral; Arthralgia; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Defer	2010
The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies. Hemoglobin, 2010, Volume: 34, Issue:3 Topics: Anti-Infective Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Infections; Iron;	2010
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. European journal of haematology, 2010, Volume: 85, Issue:4 Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone;	2010
Removal of Fe3+ and Zn2+ from plasma metalloproteins by iron chelating therapeutics depicted with SEC-ICP-AES. Dalton transactions (Cambridge, England : 2003), 2010, Aug-28, Volume: 39, Issue:32 Topics: Binding Sites; Chromatography, Gel; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents;	2010
More pieces to the iron chelation puzzle. Translational research : the journal of laboratory and clinical medicine, 2010, Volume: 156, Issue:2 Topics: Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Over	2010
Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Translational research : the journal of laboratory and clinical medicine, 2010, Volume: 156, Issue:2 Topics: Adult; Chromatography, High Pressure Liquid; Deferiprone; Deferoxamine; Female; Ferric Compounds; Hu	2010
Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood cells, molecules & diseases, 2010, Aug-15, Volume: 45, Issue:2 Topics: Adult; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therap	2010
Pathogenesis and management of iron toxicity in thalassemia. Annals of the New York Academy of Sciences, 2010, Volume: 1202 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Homeostasis; Humans; Iron; Iron Chelating Agents;	2010
Combined iron chelation therapy. Annals of the New York Academy of Sciences, 2010, Volume: 1202 Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Combinations; Ferritins; Humans	2010
Iron chelation therapy for patients with sickle cell disease and iron overload. American journal of hematology, 2010, Volume: 85, Issue:10 Topics: Administration, Oral; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Deferip	2010
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica, 2011, Volume: 96, Issue:1 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Drug	2011
Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status. Clinical pharmacokinetics, 2011, Volume: 50, Issue:1 Topics: Administration, Oral; Adult; Area Under Curve; beta-Thalassemia; Deferiprone; Female; Ferritins; Hem	2011
The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration. Investigative ophthalmology & visual science, 2011, Feb-16, Volume: 52, Issue:2 Topics: Administration, Oral; Animals; Antigens, CD; Cell Death; Cell Line; Ceruloplasmin; Deferiprone; Elec	2011
Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal. British journal of pharmacology, 2011, Volume: 164, Issue:2b Topics: Anemia, Iron-Deficiency; Animals; Antimicrobial Cationic Peptides; Biological Transport; Cation Tran	2011
Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major. Haematologica, 2011, Volume: 96, Issue:2 Topics: beta-Thalassemia; Deferiprone; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Magneti	2011
The proceedings of the 19Th international conference on chelation held in London, United Kingdom: major changes in iron chelation therapy in the last 25 years using deferiprone (L1) has resulted in the complete treatment of iron overload. Hemoglobin, 2011, Volume: 35, Issue:3 Topics: Animals; Chelation Therapy; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; London; Pyrid	2011
Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. British journal of haematology, 2011, Volume: 154, Issue:5 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Drug Therapy, Combi	2011
Allosteric effects of sulfonate anions on the rates of iron release from serum transferrin. Journal of inorganic biochemistry, 2011, Volume: 105, Issue:9 Topics: Alkanesulfonates; Allosteric Site; Anions; Binding Sites; Chelating Agents; Chelation Therapy; Defer	2011
Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2011, Jul-06, Volume: 13 Topics: Adult; Analysis of Variance; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Female;	2011
Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation. Parkinsonism & related disorders, 2012, Volume: 18, Issue:1 Topics: Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Middle Aged; Neurodegenerative Di	2012
Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia. Journal of paediatrics and child health, 2011, Volume: 47, Issue:11 Topics: Adolescent; Adult; Blood Transfusion; Child; Child, Preschool; Cohort Studies; Deferiprone; Female;	2011
Challenges of adherence and persistence with iron chelation therapy. International journal of hematology, 2011, Volume: 94, Issue:5 Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Child; Deferasir	2011
Deferiprone approved for iron overload. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2011, Nov-15, Volume: 68, Issue:22 Topics: Deferiprone; Drug Approval; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thal	2011
Use of deferiprone for the treatment of hepatic iron storage disease in three hornbills. Journal of the American Veterinary Medical Association, 2012, Jan-01, Volume: 240, Issue:1 Topics: Animals; Bird Diseases; Birds; Deferiprone; Female; Iron Chelating Agents; Iron Overload; Liver Dise	2012
The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies. Toxicology mechanisms and methods, 2013, Volume: 23, Issue:1 Topics: Chelating Agents; Chelation Therapy; Deferiprone; Deferoxamine; Edetic Acid; Humans; Iron Overload;	2013
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience. Annals of hematology, 2013, Volume: 92, Issue:2 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferip	2013
Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2. Toxicology mechanisms and methods, 2013, Volume: 23, Issue:1* Topics: Adolescent; Adult; beta-Thalassemia; Body Burden; Child; Deferiprone; Deferoxamine; Drug Therapy, Co	2013
Academic freedom in clinical research. The New England journal of medicine, 2002, Oct-24, Volume: 347, Issue:17 Topics: Canada; Confidentiality; Conflict of Interest; Deferiprone; Drug Industry; Ethics; Freedom; History,	2002
The Olivieri case. The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9 Topics: Deferiprone; Drug Approval; Interinstitutional Relations; Iron Chelating Agents; Iron Overload; Pyri	2003
Treatment of cardiac iron overload in thalassemia major. Haematologica, 2003, Volume: 88, Issue:5 Topics: beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Dise	2003
Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica, 2003, Volume: 88, Issue:5 Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Disease-Free Survival; Female	2003
Deferiprone and hepatic fibrosis. Blood, 2003, Jun-15, Volume: 101, Issue:12 Topics: Deferiprone; Humans; Iron Overload; Liver Cirrhosis; Pyridones	2003
Do we need more iron-chelating drugs? Lancet (London, England), 2003, Aug-09, Volume: 362, Issue:9382 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyr	2003
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Annals of hematology, 2004, Volume: 83, Issue:7 Topics: Adult; beta-Thalassemia; Cardiovascular Agents; Deferiprone; Deferoxamine; Diabetes Complications; D	2004
Iron: a target for the management of Kaposi's sarcoma? BMC cancer, 2004, Jan-15, Volume: 4 Topics: Africa; Deferiprone; Deferoxamine; Female; Herpesvirus 8, Human; Humans; Iron Chelating Agents; Iron	2004
Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation. Gut, 2004, Volume: 53, Issue:5 Topics: Adult; Ceruloplasmin; Chelation Therapy; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating A	2004
Clinical evaluation of the oral iron chelator deferiprone for the potential treatment of iron overload in bird species. Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians, 2004, Volume: 35, Issue:1 Topics: Administration, Oral; Animals; Chickens; Columbidae; Deferiprone; Dose-Response Relationship, Drug;	2004
Iron chelation therapy. Current hematology reports, 2005, Volume: 4, Issue:2 Topics: Administration, Oral; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Live	2005
The Egyptian experience with oral iron chelators. Hematology (Amsterdam, Netherlands), 2005, Volume: 10 Suppl 1 Topics: Benzoates; Deferasirox; Deferiprone; Egypt; Humans; Iron Chelating Agents; Iron Overload; Pyridones;	2005
Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica, 2005, Volume: 90, Issue:10 Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agent	2005
Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica, 2005, Volume: 90, Issue:10 Topics: Adolescent; Adult; Agranulocytosis; beta-Thalassemia; Cardiovascular Diseases; Child; Deferiprone; D	2005
[Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy]. Revista espanola de cardiologia, 2006, Volume: 59, Issue:1 Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Heart Failure; Humans; Iron C	2006
New chelation therapies and emerging chelating drugs for the treatment of iron overload. Expert opinion on emerging drugs, 2006, Volume: 11, Issue:1 Topics: beta-Thalassemia; Carboxylic Acids; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Design	2006
Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation. Hemoglobin, 2006, Volume: 30, Issue:1 Topics: Adolescent; Anemia, Sideroblastic; Biomarkers; Bone Marrow Transplantation; Chelation Therapy; Combi	2006
Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs. Haematologica, 2006, Volume: 91, Issue:6 Suppl Topics: Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload;	2006
Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Adolescent; Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Chelatio	2006
Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Adolescent; Adult; Alanine Transaminase; beta-Thalassemia; Biomarkers; Biopsy; Chelation Therapy; Ch	2006
Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Adolescent; Adult; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Child; Combined Modality T	2006
Thalassemia treatment and prevention in Uva Province, Sri Lanka: a public opinion survey. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Abortion, Eugenic; Adolescent; Adult; Blood Transfusion; Chelation Therapy; Combined Modality Therap	2006
Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Activities of Daily Living; Adaptation, Psychological; Administration, Oral; Adolescent; Adult; Atti	2006
Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Adaptation, Psychological; Administration, Oral; Adolescent; Adult; Attitude to Health; beta-Thalass	2006
Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. British journal of haematology, 2006, Volume: 134, Issue:4 Topics: Adolescent; Adult; Analysis of Variance; beta-Thalassemia; Blood Glucose; Chelation Therapy; Child;	2006
Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats. Human & experimental toxicology, 2006, Volume: 25, Issue:7 Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Ascorbic Acid; Deferiprone; Deferoxamine; Deoxyg	2006
Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Translational research : the journal of laboratory and clinical medicine, 2006, Volume: 148, Issue:5 Topics: Animals; Benzoates; Deferasirox; Deferiprone; Disease Models, Animal; Female; Gerbillinae; Heart; Ir	2006
[Post transfusionnal iron overload]. La Revue du praticien, 2006, Dec-15, Volume: 56, Issue:19 Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Erythrocyte Transfusion; Humans; Iron Chelati	2006
Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin, 2008, Volume: 32, Issue:1-2 Topics: Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iron; Iro	2008
Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia. Hemoglobin, 2008, Volume: 32, Issue:1-2 Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Fe	2008
Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment. Hemoglobin, 2008, Volume: 32, Issue:1-2 Topics: Adolescent; Adult; Autoantibodies; B-Lymphocytes; beta-Thalassemia; Chelation Therapy; Child; Deferi	2008
Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin, 2008, Volume: 32, Issue:1-2 Topics: Adult; Chelation Therapy; Clinical Protocols; Deferiprone; Deferoxamine; Drug Therapy, Combination;	2008
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica, 2008, Volume: 93, Issue:5 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Decision Support Techniques; Deferasirox; Def	2008
Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non-transferrin-bound iron in rats. Hepatology (Baltimore, Md.), 1997, Volume: 25, Issue:6 Topics: Animals; Bile; Deferiprone; Ferric Compounds; Injections, Intravenous; Intestinal Absorption; Intest	1997
The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. Blood, 1998, Jul-15, Volume: 92, Issue:2 Topics: Cell Line; Deferiprone; DNA Damage; Humans; Iron Chelating Agents; Iron Overload; Liver; Oxidative S	1998
Iron-chelation therapy with oral deferiprone--toxicity or lack of efficacy? The New England journal of medicine, 1998, Aug-13, Volume: 339, Issue:7 Topics: Administration, Oral; beta-Thalassemia; Biopsy; Deferiprone; Humans; Iron; Iron Overload; Liver; Liv	1998
Constraints of interest: lessons at the Hospital for Sick Children. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1998, Oct-20, Volume: 159, Issue:8 Topics: beta-Thalassemia; Biomedical Research; Canada; Clinical Trials as Topic; Conflict of Interest; Contr	1998
Legal issues surrounding privately funded research cause furore in Toronto. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1998, Oct-20, Volume: 159, Issue:8 Topics: beta-Thalassemia; Biomedical Research; Canada; Clinical Trials as Topic; Conflict of Interest; Contr	1998
Iron chelation with oral deferiprone in patients with thalassemia. The New England journal of medicine, 1998, Dec-03, Volume: 339, Issue:23 Topics: beta-Thalassemia; Biopsy; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Liver Cirrhosis	1998
Iron chelation with oral deferiprone in patients with thalassemia. The New England journal of medicine, 1998, Dec-03, Volume: 339, Issue:23 Topics: beta-Thalassemia; Biopsy; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Liver; Liver Ci	1998
Iron chelation with oral deferiprone in patients with thalassemia. The New England journal of medicine, 1998, Dec-03, Volume: 339, Issue:23 Topics: beta-Thalassemia; Biopsy; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Liver; Liver Ci	1998
Iron chelation with oral deferiprone in patients with thalassemia. The New England journal of medicine, 1998, Dec-03, Volume: 339, Issue:23 Topics: beta-Thalassemia; Biopsy; Deferiprone; Deferoxamine; Ferritins; Humans; Iron Chelating Agents; Iron	1998
Iron chelation with oral deferiprone in patients with thalassemia. The New England journal of medicine, 1998, Dec-03, Volume: 339, Issue:23 Topics: beta-Thalassemia; Deferiprone; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Liver Cirr	1998
Iron chelation with oral deferiprone in patients with thalassemia. The New England journal of medicine, 1998, Dec-03, Volume: 339, Issue:23 Topics: beta-Thalassemia; Deferiprone; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver;	1998
Iron chelation with oral deferiprone in patients with thalassemia. The New England journal of medicine, 1998, Dec-03, Volume: 339, Issue:23 Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyr	1998
Effect of transfusion on lipid peroxidation products in the plasma of thalassemic patients. Transfusion, 1999, Volume: 39, Issue:3 Topics: Aldehydes; beta-Thalassemia; Biomarkers; Chelation Therapy; Deferiprone; Deferoxamine; Erythrocyte T	1999
Deferiprone for thalassaemia. Lancet (London, England), 2000, Jul-29, Volume: 356, Issue:9227 Topics: Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia	2000
The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1). Transfusion science, 2000, Volume: 23, Issue:3 Topics: Australia; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reactio	2000
Competition studies of L1-deferiprone with copper and iron. Possible implications on efficacy, toxicity and new therapeutic applications. Transfusion science, 2000, Volume: 23, Issue:3 Topics: Copper; Deferiprone; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones	2000
Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood, 2001, Feb-01, Volume: 97, Issue:3 Topics: Adolescent; Adult; Apoproteins; Calibration; Chelation Therapy; Child; Deferiprone; Deferoxamine; Dr	2001
Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. Journal of chromatography. B, Biomedical sciences and applications, 2001, May-05, Volume: 755, Issue:1-2 Topics: Benzoates; Calibration; Chromatography, High Pressure Liquid; Deferasirox; Deferiprone; Deferoxamine	2001
Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. The Journal of laboratory and clinical medicine, 2001, Volume: 138, Issue:2 Topics: Animals; Blood Transfusion; Cells, Cultured; Deferiprone; Deferoxamine; Dose-Response Relationship,	2001
The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice. Toxicology letters, 2002, Mar-10, Volume: 128, Issue:1-3 Topics: Animals; Catalase; Deferiprone; Deferoxamine; Glutathione; Glutathione Peroxidase; Iron Chelating Ag	2002
The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. The Journal of laboratory and clinical medicine, 2002, Volume: 139, Issue:1 Topics: Animals; Deferiprone; Deferoxamine; Disease Models, Animal; Female; Gerbillinae; Iron Chelating Agen	2002

deferiprone and Iron Overload